Treatment composition containing esteramine or its salt

Abstract

A treatment composition comprising at least one fragrance raw material and an esteramine or a salt thereof, which may be obtained by a process using a catalytic amount of at least one orthoester, and a method for treating an article or surface, optionally comprising treating the article or surface with such treatment composition in the presence of water.

Description

[Technical Field]

[0001] This disclosure relates to a treatment composition comprising at least one fragrance raw material and an esteramine or a salt thereof, and to a method for treating an article or surface using such a composition. The esteramine may be obtained by using a catalytic or substoichiometric amount of an orthoester. [Background technology]

[0002] Consumers prefer treated products (e.g., fabric treatment compositions, hard surface treatment compositions, etc.) that have a remarkably pleasant fragrance. The consumer products industry is continuously seeking ways to improve the delivery efficiency and / or performance effects related to fragrance ingredients contained in such treatment compositions. The use of fragrance delivery systems (e.g., pro-fragrances) can be a useful strategy for improving delivery efficiency. Therefore, there remains interest in novel and improved fragrance delivery systems for use in treatment compositions.

[0003] Furthermore, with growing environmental awareness, consumers desire products that align with desirable environmental or sustainability profiles. Therefore, several key goals for the consumer products industry include utilizing more biodegradable ingredients, improving the sustainability of cleaning formulations, avoiding the accumulation of non-degradable compounds in ecosystems, and reducing CO2 emissions associated with the manufacture or use of consumer products. Consequently, providing consumer products that are more environmentally friendly without sacrificing performance remains essential. [Overview of the project] [Problems that the invention aims to solve]

[0004] There is a continued need for treatment compositions that, in combination, enhance environmental friendliness while enabling good / improved fragrance delivery performance, and that include a fragrance delivery system. Furthermore, there is a need for methods of manufacturing and using such treatment compositions. [Means for solving the problem]

[0005] This disclosure relates to a processed composition comprising at least one fragrance raw material and an esteramine of formula (I) or a salt thereof,

[0006] [ka] During the ceremony, they act independently of each other. t is an integer between 1 and 100; A1 is independently selected for each repeating unit t from the list consisting of ethyleneoxy group, 1,2-propyleneoxy group, 1,2-butyleneoxy group, 2,3-butyleneoxy group, i-butyleneoxy group, pentyleneoxy group, hexyleneoxy group, styryloxy group, decenyloxy group, dodecenyloxy group, tetradecenyloxy group, and hexadecanyloxy group, and when t is equal to 1, the oxygen atom of the A1 group is bonded to the B group, and the next A1 group is always bonded to the previous A1 group via an oxygen atom; B1 is linked to each other independently, forming a linear chain C1~C 12 Alkanediyl group, and branched C1-C 12 Selected from the group consisting of alkanediyl groups; R4, R8, and R 12 This is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; However, Z1 is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and compounds according to formula (II):

[0007] [ka] [In the formula, they are independent of each other, w is an integer between 0 and 12; R 13 and R 14is independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl for each repeating unit w; R 15 、R 16 、R 17 、and R 18 is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl] is selected from the group consisting of, and the compound according to formula (II) is * connected to the compound according to formula (I) via a bond labeled with, provided that at least one of the R4, R8, and / or R 12 groups contains at least 7 or more carbon atoms, relating to a treatment composition.

[0008] This disclosure also relates to a processed composition comprising at least one fragrance raw material and an esteramine or salt thereof obtained by a method using at least one orthoester in a catalytic amount, wherein the method is 1) α-, β-, alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamate, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine, etc. At least one amino acid selected from γ-, δ-, ε-amino acids; α-amino acids having secondary or tertiary amino groups such as sarcosine and N,N-dimethylglycine; other amino acids such as 6-aminohexanoic acid, 4-aminobutanoic acid, 3-aminopropanoic acid, 12-aminododecanoic acid, and 11-aminoundecanoic acid; and amino acids formally derived from hydrolysis of α-lactams (3 ring atoms), β-lactams (4 ring atoms), γ-lactams (5 ring atoms), etc., wherein such lactams are preferably 1) At least one amino acid, which is β-propiolactam, γ-butyrolactam, δ-valerolactam, γ-valerolactam, e-caprolactam, d-decalactam, γ-decalactam, or e-decalactam; preferably, alanine, valine, β-alanine, or 6-aminohexanoic acid; 2) At least one alcohol (A) having at least one hydroxyl group, selected from mono-, di-, and polyols, all of which may optionally be alkoxylated, and at least one hydroxyl group The alkoxylation of the hydroxyl group is carried out in a step prior to step a), and the alcohol is alkoxylated with at least one alkylene oxide per hydroxyl group, preferably at least 1 and up to 200, preferably 1 to 100, more preferably up to 50 moles of alkylene oxide, and 3) at least one acid (C) selected from inorganic and organic acids, wherein the organic or inorganic acid is preferably -3 to +5, more preferably -2.5 to 1.The process includes: 1) obtaining an esteramine salt by reaction in the presence of at least one organic acid having a pKa value in the range of 5, preferably such as a sulfonic acid, more preferably an alkyl sulfonic acid, and / or an aryl sulfonic acid; 2) obtaining an esteramine salt by reaction in the presence of at least one orthoester such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, wherein the orthoester is used in less than a stoichiometric amount, preferably a catalytic amount (relative to the amino acid), and the alcohol used for esterification is different from the alcohol residue in the orthoester; and 3) producing an esteramine salt. Optionally, an additional step may exist in which the obtained esteramine salt is neutralized with at least one base to obtain a free esteramine. The processed composition contains less than 0.5% alcohol (A) by weight of the processed composition as a residue of the reaction process that obtained the esteramine or its salt.

[0009] The disclosure also relates to a method for treating an article or surface, the method comprising treating the article or surface with a treatment composition according to the disclosure, optionally in the presence of water. [Modes for carrying out the invention]

[0010] This disclosure relates to a treatment composition comprising at least one fragrance ingredient and an esteramine or a salt thereof, and to a method of treating an article or surface by using such a composition. In some embodiments of the treatment composition, a portion of at least one fragrance ingredient may be bonded to the esteramine or a salt thereof by linking bonds at some point (e.g., when added together as a premix, when added together in a consumer product bottle, when in contact with an article or surface, in the scrubbing portion of a hard surface cleaning process, in the washing process of a fabric laundry, in the drying process). Although not bound by theory, it is believed that when the linking bonds are broken (e.g., via hydrolysis or a reverse reaction), the fragrance ingredient is released, delivering the benefit of fragrance delivery.

[0011] Such treatment compositions and related methods of use are described in more detail below. Such treatment compositions utilize esteramines and their salts obtained by the methods detailed herein. Treatment compositions using esteramines and their salts obtained by the reaction processes detailed herein have less residual fatty alcohol (i.e., alcohol (A) as defined herein) compared with esteramines and their salts obtained by different known reaction processes (e.g., esteramines synthesized without such orthoesters). Therefore, due to the lower amount of residual fatty alcohol in the treatment compositions, the treatment compositions have a better base odor. This can be confirmed by GC / MS (gas chromatography / mass spectrometry) headspace analysis comparing treatment compositions where only the source of the esteramine and its salt differs, and where the source differs depending on the reaction process from which the esteramine and its salt are derived.

[0012] Furthermore, for stability reasons, the methods detailed herein may preferably use primary and secondary alcohols in the reactant, which is at least one alcohol (A). Using primary and secondary alcohols in the reactant, which is at least one alcohol (A), also results in a processed composition containing residual primary and secondary alcohols that were not converted to esteramines and their salts. Esteramines obtained with primary and secondary alcohols have improved stability compared to other esteramines.

[0013] Clearly, esteramines and their salts obtained by the methods detailed herein (and esteramines and their salts obtained by known methods using stoichiometric amounts of orthoesters) can be further purified to remove even more residual fatty alcohols and thus improve the base odor of the treatment compositions in which they are used. However, each purification step consumes more energy and makes the resulting consumer product unenvironmentally friendly. Therefore, the ability to use esteramines and their salts obtained by the methods defined herein in the treatment compositions detailed herein without additional purification steps allows for acceptable, more environmentally friendly treatment compositions. In other words, such treatment compositions utilizing esteramines obtained by the processes detailed herein also have a lower CO2 footprint compared to esteramines produced through alternative processes. In addition to the above benefits, such esteramines and their salts exhibit good biodegradability when used in treatment compositions, e.g., fabric treatment compositions.

[0014] Definition: When used herein, the articles “a” and “an” as used in the claims are understood to mean one or more of the claimed or described items. When used herein, the terms “include,” “includes,” and “including” are meant to be non-limiting. The compositions of the disclosure may include, be essentially composed of, or consist of the components of the disclosure.

[0015] In this specification, the terms “substantially free of” or “substantially free from” may also be used. This means that the indicated material is present in minimal amounts and is not intentionally added to the composition to form part of the composition, or preferably not present in an analytically detectable concentration. It means that the indicated material is present only as an impurity in one of the other materials that are intentionally included. If the indicated material is present, it may be present in a concentration of less than 1% by weight, less than 0.1% by weight, less than 0.01% by weight, or even 0% by weight of the composition.

[0016] Specifically, the term "water-free" means that the composition contains 5% by weight or less of water based on the total amount of solvent, in another embodiment, 1% by weight or less of water based on the total amount of solvent, and in a further embodiment, the solvent contains no water at all.

[0017] Generally, as used herein, the term “obtainable by” means that the corresponding product does not necessarily have to be manufactured (i.e., obtained) by the corresponding method or process described in each particular context. However, it also includes products that exhibit all the characteristics of a product manufactured (obtained) by the corresponding method or process, even if they were not actually manufactured (obtained) by such a method or process. However, the term “obtainable by” also includes the more restrictive term “obtained by,” which also includes products that are actually manufactured (obtained) by the method or process described in each particular context.

[0018] Where used herein, any definition requiring a compound or substituent of a compound to consist of "at least [a certain number] carbon atoms" refers to the total number of carbon atoms in the compound or substituent of a compound. For example, for a substituent disclosed as "an alkyl ether having at least eight carbon atoms and comprising an alkylene oxide group," the total number of at least eight carbon atoms must be the sum of the number of carbon atoms in the alkyl moiety and the number of carbon atoms in the alkylene oxide moiety.

[0019] All such terms that are not specifically defined have their usual meanings as they are known in the field of organic chemistry.

[0020] The term "contains one hydroxyl group" means that only one -OH group is present. Functional groups derived from hydroxyl groups, such as ether groups, are not considered -OH groups.

[0021] The phrase "containing at least two hydroxyl groups" means the presence of two or more -OH groups. The term "hydroxyl group" is equivalent to the terms "hydroxyl group" or "-OH group". Alcohols / compounds having only one hydroxyl group, such as methanol or ethanol, consequently do not meet the definition of an alcohol containing at least two hydroxyl groups as defined by compound (A) of this disclosure. Functional groups derived from hydroxyl groups, such as ether groups, are not considered -OH groups.

[0022] In this disclosure, “sulfonate” is an anion derived from a sulfonic acid, preferably an alkylsulfonic acid and / or an arylsulfonic acid, more preferably an alkylsulfonic acid, most preferably a methanesulfonic acid, such an acid is used to at least partially protonate an esteramine, and thus form a sulfonate of the esteramine.

[0023] As used herein, the articles “a” and “an” used in the claims or embodiments are understood to mean one or more of the claimed or described items. As used herein, the terms “include(s)” and “including” are intended to be non-restrictive and therefore encompass more than the specific items mentioned after those words.

[0024] When used herein, the term “about” refers to an exact number “X” as mentioned, for example, “about X%”, as well as small variations in X, including deviations of minus 5 to plus 5% from X (in this calculation, X is set to 100%), preferably minus 2 to plus 2%, more preferably minus 1 to plus 1%, even more preferably minus 0.5 to plus 0.5%, and smaller variations. Of course, if a given value X itself is already “100%” (in terms of purity, etc.), the term “about” can obviously mean its deviation less than “100”, and therefore only that deviation.

[0025] As used herein, “treatment composition” includes consumer product compositions used to treat one or more surfaces. The treatment compositions of the Disclosure may be useful in infant care, cosmetic care, fabric care, home care, family care, women’s care, and / or healthcare applications, and may be used, for example, to treat hard surfaces, soft surfaces, fabrics, hair, and / or skin. For clarity, the term “treatment composition” is a comprehensive term that includes non-limiting examples such as “fabric treatment composition,” “fabric care composition,” and “hard surface treatment composition.”

[0026] As used herein, the term “fabric care composition” includes compositions and formulations designed for treating fabrics. Such compositions include, but are not limited to, laundry cleaning compositions and detergents, fabric softening compositions, fabric strengthening compositions, fabric deodorizing compositions, pre-wash detergents, pre-wash treatments, laundry additives, spray products, dry cleaning agents or compositions, wash rinse additives, washing additives, post-rinse fabric treatments, ironing aids, unit-dose formulations, delayed-delivery formulations, detergents contained on or in porous substrates or nonwoven sheets, and other suitable forms that may be apparent to those skilled in the art in consideration of the teachings herein. Such compositions may be used as pre-wash treatments, post-wash treatments, or added during the rinse or wash cycle of a laundry operation.

[0027] Unless otherwise noted, all concentrations of components or compositions refer to the active portion of that component or composition, excluding impurities that may be present in the commercially available source of such components or compositions, such as residual solvents or by-products.

[0028] All temperatures in this specification are in degrees Celsius (°C) unless otherwise specified. Unless otherwise specified, all measurements in this specification are performed at 20°C and atmospheric pressure.

[0029] In all embodiments of this disclosure, all percentages are relative to the total weight of the composition unless otherwise specifically stated. Unless otherwise specifically stated, all ratios are by weight.

[0030] It should be understood that all maximum numerical limits given throughout this specification include all lower numerical limits as if they were explicitly stated herein. All minimum numerical limits given throughout this specification include all higher numerical limits as if they were explicitly stated herein. All numerical ranges given throughout this specification include all narrow numerical ranges that fall within such broad numerical ranges as if they were explicitly stated herein.

[0031] Structures of esteramines and their salts: The treatment compositions detailed herein relate to alkoxylated esteramines of formula (I) and their salts,

[0032] [ka] During the ceremony, they act independently of each other. t is an integer between 1 and 100; A1 is independently selected for each repeating unit t from the list consisting of an ethyleneoxy group, a 1,2-propyleneoxy group, a 1,2-butyleneoxy group, a 2,3-butyleneoxy group, an i-butyleneoxy group, a pentyleneoxy group, a hexyleneoxy group, a styryloxy group, a decenyloxy group, a dodecenyloxy group, a tetradecenyloxy group, and a hexadecanyloxy group. When t is equal to 1, the oxygen atom of the A1 group is bonded to the B group, and the next A1 group is always bonded to the previous A1 group via an oxygen atom.

[0033] B1 is linked to each other independently, forming a linear chain C1~C 12 Alkanediyl group, and branched C1-C 12 Selected from the group consisting of alkanediyl groups; R4, R8, and R 12 This is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; However, Z1 is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and compounds according to formula (II):

[0034] [ka] [In the formula, they are independent of each other, w is an integer between 0 and 12; R 13 and R 14 Each repeating unit w is independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; R 15 , R 16 , R 17 , and R 18 [Selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl] A compound is selected from the group consisting of the following, and the compound according to formula (II) is * The compound is linked to the compound of formula (I) via a bond labeled with R4, R8, and / or R 12 At least one of the groups contains at least seven or more carbon atoms.

[0035] The esteramines and salts thereof according to this disclosure may be used in treatment compositions, particularly in liquid fabric improvers. In some embodiments of the treatment compositions, a portion of at least one fragrance ingredient may be bonded to the esteramine or salt thereof by linking bonds. While not bound by theory, it is believed that when the linking bond is broken (e.g., via hydrolysis or a reverse reaction), the fragrance ingredient is released, delivering the benefit of fragrance delivery. Therefore, the esteramines and salts thereof described herein may be used as part of professional fragrance technology.

[0036] Various embodiments of this disclosure are described in more detail below.

[0037] A1 is independently selected for each repeating unit t from a list consisting of ethyleneoxy group, 1,2-propyleneoxy group, 1,2-butyleneoxy group, 2,3-butyleneoxy group, i-butyleneoxy group, pentenyloxy group, hexyloxy group, styryloxy group, decenyloxy group, dodecyloxy group, tetradecenyloxy group, and hexadecenyloxy group. When t is equal to 1, the oxygen atom of the A1 group is bonded to the B group, and the next A1 group is always bonded to the previous A1 group via an oxygen atom. When t is 2 or greater, the independently selected A1 either forms a randomly distributed side chain of various alkenyloxy units, or forms a block structure having at least one alkenyloxy group repeating itself at least twice, and then optionally forms a further block of different alkenyloxy groups repeating themselves at least twice.

[0038] In one embodiment, A1 is independently selected for each repeating unit t from a list consisting of an ethyleneoxy group, a 1,2-propyleneoxy group, a 1,2-1,2-propyleneoxy group, and a 1,2-butyleneoxy group. In another embodiment, A1 forms each block of at least two ethyleneoxy groups, followed by a block of at least two propyleneoxy groups, and then optionally another block of at least two ethyleneoxy groups. In yet another embodiment, A1 forms each block of at least two 1,2-propyleneoxy groups, followed by a block of at least two ethyleneoxy groups, and then optionally another block of at least two 1,2-propyleneoxy groups. In another embodiment, A1 is selected from a list consisting of ethyleneoxy groups, 1,2-propyleneoxy groups, and 1,2-butyleneoxy groups in such a way that at least one block of ethyleneoxy groups, 1,2-propyleneoxy groups, or 1,2-butyleneoxy groups is formed, followed optionally by the formation of one or more blocks of ethyleneoxy groups, 1,2-propyleneoxy groups, or 1,2-butyleneoxy groups. In another embodiment, A1 is an ethyleneoxy group. In another embodiment, A1 is a 1,2-propyleneoxy group. In another embodiment, A1 is selected such that a block of 1 to 5 ethyleneoxy groups is followed by a block of 1 to 3 propyleneoxy groups, followed by a block of 1 to 5 ethyleneoxy groups.

[0039] In one embodiment, t is in the range of 1 to 30. In another embodiment, t is in the range of 1 to 20. In yet another embodiment, t is in the range of 2 to 10.

[0040] In one embodiment of this disclosure, B1 is bonded, and linear C1-C 12It is selected from the group consisting of alkanediyl groups. In another embodiment, B1 is selected from the group consisting of a bond and linear C1-C6 alkanediyl groups. In another embodiment, B1 is selected from the group consisting of a bond and linear C1-C3 alkanediyl groups. In another embodiment, B1 is selected from the group consisting of a bond and a C1 alkanediyl group. In another embodiment, B1 is selected from the group consisting of a bond and a C1 alkanediyl group. In another embodiment, B1 is a bond.

[0041] In one embodiment of the present disclosure, R4, R8, and R 12 These are all independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl. In one embodiment, R4, R8, and R 12 These are all independent, H, linear C1-C 12 Alkyl and C1-C 12 Selected from the group consisting of branched alkyl groups. In another embodiment, R4, R8, and R 12 These are all independently selected from the group consisting of H, linear C1-C6 alkyl groups, and C1-C9 branched alkyl groups.

[0042] For Z1 selected from the compounds according to formula (II), the compound according to formula (II) is: * The compound of formula (I) is connected via a bond labeled with,

[0043] [ka] [In the formula, they are independent of each other, w is an integer between 0 and 12; R 13 and R 14 Each repeating unit w is independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; R 15 , R 16 , R 17 , and R 18[is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl]. In one embodiment of the present invention, R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 These are all independent, H, linear C1-C 12 Alkyl and C1-C 12 Selected from the group consisting of branched alkyl groups. In another embodiment, R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 These are all independently selected from the group consisting of H, linear C1-C6 alkyl groups, and C1-C9 branched alkyl groups.

[0044] In one embodiment of the present disclosure, Z1 is selected from the group consisting of alanine, glycine, lysine, and a compound according to formula (II), w is an integer in the range of 1 to 4, and the compound according to formula (II) is * The compound is linked to the compound of formula (I) via a bond labeled with, provided that at least one group R4, R8, and / or R 12 It contains at least 7 or more carbon atoms. In another embodiment, Z1 is alanine. In another embodiment, Z1 is w=0 and R 15 ~R 18 The compound is of formula (II), where all are H. In another embodiment, Z1 is w=1, and R 13 ~R 18 The compound is of formula (II), where all are H. In another embodiment, Z1 is w=3, and R 13 ~R 18 This is a compound according to formula (II), where all atoms are H.

[0045] In another embodiment of the present disclosure, B1 is a branched or linear C1-C 12 Selected from alkyl groups, R8 is linear or branched C6-C 23Selected from alkyl groups. In another embodiment of this disclosure, B1 is branched or linear C1-C 12 -Selected from alkyl groups, R8 is selected from linear or branched C1-~C3 alkyl groups. Another embodiment consists of B1 being 2-ethyl-ethanediyl and R8 being a linear C3 alkyl group.

[0046] In another embodiment of the present disclosure, B1 is a branched or linear C1-C 12 Selected from alkyl groups, R8 is selected from linear or branched C1-C3 alkyl groups, Z1 is a compound of formula (II) with w=3, and R 13 ~R 18 All of them are H.

[0047] In another embodiment of the present disclosure, B1 is a branched or linear C6-~C 12 Selected from alkyl groups, R8 is selected from linear or branched C1-C3 alkyl groups, t is in the range of 1-10, A1 is the ethyleneoxy group of each repeating unit t, Z1 is alanine, w=0, and R 15 ~R 18 Compounds according to formula (II) that all contain H, w=1, and R 13 ~R 18 Compounds according to formula (II) that all contain H, as well as w=3 and R 13 ~R 18 The compounds are selected from the group consisting of compounds of formula (II) that all contain H.

[0048] In another embodiment of the present disclosure, B1 is a branched or linear C6-C 12 Selected from alkyl groups, R8 is selected from linear or branched C1-C3 alkyl groups, R4 and R 12 is selected from H and linear or branched C1-C3 alkyl groups, t is in the range of 1-10, A1 is the 1,2-propyleneoxy group of each repeating unit t, Z1 is alanine, w=0, and R 15 ~R 18 Compounds according to formula (II) that all contain H, w=1, and R 13 ~R 18Compounds according to formula (II) that all contain H, as well as w=3 and R 13 ~R 18 The compounds are selected from the group consisting of compounds of formula (II) that all contain H.

[0049] The esteramines according to this disclosure can be obtained as free amines, as salts thereof, or as mixtures of free amines and salts. The salts are formed by at least partial protonation of the amine group with an acid which is a protic organic acid or a protic inorganic acid. In one embodiment, the acid for at least partial protonation of the amine group is selected from the group consisting of methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, and lactic acid. In one embodiment, the acid is selected from the group consisting of methanesulfonic acid, hydrochloric acid, and sulfuric acid. In another embodiment, the acid is methanesulfonic acid.

[0050] In one embodiment, partial protonation is the protonation of amine groups in the range of 1 to 99 mol% of all amine groups; in another embodiment, in the range of 10 to 90 mol% of all amine groups; in yet another embodiment, in the range of 25 to 85 mol%; and in yet another embodiment, in the range of 40 to 75 mol% of all amine groups.

[0051] Process for producing esteramines and their salts: Surprisingly, it has been found that the esterification of amino acids can be improved by using substoichiometric or even catalytic amounts of orthoester. Furthermore, unexpectedly, the ester can produce esteramines derived from an alcohol other than the alcohol present in the orthoester used as a catalyst. Therefore, this disclosure relates to an improved process for producing esteramines and their salts using substoichiometric or catalytic amounts of orthoester.

[0052] Therefore, the present disclosure relates to a treatment composition comprising an esteramine or a salt thereof, which is produced by using a catalytic amount of at least one orthoester, and the method is as follows: a) i) α-, β-, γ-, δ-, ε-amino acids such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamate, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, and serine; α-amino acids having secondary or tertiary amino groups such as sarcosine and N,N-dimethylglycine; 6-aminohexanoic acid, 4-aminobutanoic acid, 3-aminopropanoic acid, 12-aminododecanoic acid, and 11-aminoundecanoic acid. At least one amino acid selected from other amino acids such as hydroxy acids; amino acids formally derived from hydrolysis of α-lactams (3 ring atoms), β-lactams (4 ring atoms), γ-lactams (5 ring atoms), etc., wherein such lactams are preferably β-propiolactam, γ-butyrolactam, δ-valerolactam, γ-valerolactam, e-caprolactam, d-decalactam, γ-decalactam, e-decalactam; preferably at least one amino acid is alanine, valine, β-alanine, 6-aminohexanoic acid, ii) At least one alcohol having at least one hydroxyl group, selected from mono-, di-, and polyols, all of which may optionally be alkoxylated, wherein the alkoxylation of at least one hydroxyl group is performed in a step prior to step a), and the alcohol is alkoxylated with at least one alkylene oxide per hydroxyl group, preferably at least 1 and up to 200, preferably 1 to 100, more preferably up to 50 moles of alkylene oxide, iii) At least one acid (C) selected from inorganic and organic acids, wherein the organic or inorganic acid preferably has a pKa value in the range of -3 to +5, more preferably -2.5 to 1.5, preferably at least one organic acid such as a sulfonic acid, more preferably an alkyl sulfonic acid and / or an aryl sulfonic acid, most preferably a methanesulfonic acid. In the presence of, iv) In the presence of at least one orthoester such as triethyl orthoformate, trimethyl orthoformate, A step to obtain an esteramine salt by the reaction, On the other hand, orthoesters are used in amounts less than stoichiometric, preferably catalytic amounts (relative to the amount of amino acids). On the other hand, the alcohol used in esterification is different from the alcohol residue in the orthoester, and the process is different. The process of producing an esteramine salt; b) Optionally, remove water and / or excess alcohol during and / or after the reaction to obtain a purified esteramine salt; c) The present invention relates to a treatment composition comprising the optional step of neutralizing the obtained esteramine salt with at least one base to obtain a free esteramine.

[0053] Furthermore, the following process steps may be optionally included in the processes disclosed herein.

[0054] The reaction mixture can be deactivated before and / or during the reaction, preferably before the addition of acid C. Deactivation can be achieved by vaporizing a gas such as nitrogen or argon and / or by adding an oxygen scavenger compound. Such oxygen scavengers are known. Advantageous is the use of a small amount of inorganic salt having reducing properties towards oxygen, such as hypophosphorous compounds, such as hypophosphorous acid or any of their salts, particularly alkalis, or ammonium or alkaline earth metal salts, more preferably acids, which can be added to the reaction mixture before the addition of sulfuric acid. One effect of this addition of an oxygen scavenger compound is that it results in an improved color of the resulting product, i.e., this means a reduction in discoloration compared to when such an addition is omitted.

[0055] The reaction takes place in the presence of the following: -50 to 200°C, preferably 70 to 180°C, more preferably 80 to 160°C, most preferably at temperatures between 120°C and 150°C, such as 60, 65, 75, 85, 90, 95, 100, 110, 115, 120, 125, 130, 135, 140, 145, 155, 165, 170, 190°C; - Over a period of time such as 1 to 30 hours, preferably from 2 hours, more preferably from 3 hours, even more preferably at least 5 hours, preferably up to 48 hours, more preferably up to 20 hours, even more preferably up to 15 hours, preferably 3 to 24 hours, more preferably 5 to 24 hours, most preferably 10 to 24 hours; The procedure is carried out at pressures ranging from -0.001 bar, more preferably from 0.005 bar, even more preferably from 0.1 bar, preferably up to 8 bar, more preferably up to 5 bar, even more preferably up to 4 bar, etc., in the range of 1 to 10 bar, more preferably 1 to 5 bar, even more preferably 1 to 4 bar, or 0.001 to 10 bar, such as 1 to 1000 mbar, more preferably 100 to 500 mbar.

[0056] Preferably, temperature, time, and pressure are all as previously defined individually, preferably within a preferred range for all three parameters, more preferably within a more preferred range for all three parameters, and so on. In one embodiment, the temperature is kept constant throughout the reaction. In another embodiment, the temperature varies within a temperature range throughout the reaction.

[0057] In one embodiment, the reaction with acid C is carried out under atmospheric pressure. In another embodiment, the reaction with acid C is carried out in a sealed container under a pressure of 0.001 to 1 bar. In yet another embodiment, the reaction with acid C is carried out in a sealed container under a pressure of more than 1 bar to 10 bar.

[0058] In one embodiment, the reaction is carried out using a protective atmosphere of an inert gas, such as nitrogen gas or argon gas.

[0059] In another embodiment, deactivation is carried out by adding an oxygen scavenger, preferably a small amount of inorganic salt having reducing properties with respect to oxygen, such as hypophosphite compounds, such as hypophosphorous acid, or any of their salts, particularly an alkali, or ammonium, or alkaline earth salt, more preferably an acid, a hypophosphite compound, more preferably hypophosphorous acid. In another embodiment, deactivation is carried out using a protective atmosphere of a previously defined inert gas by adding a previously defined oxygen scavenger.

[0060] It is clear that temperature, pressure, and time can be selected independently of the disclosed values ​​and ranges and can be combined with each other. Similarly, the method by which inactivation is achieved can also be selected and combined with the selected temperature, time, and pressure (all as previously defined).

[0061] During or after the reaction, preferably at least during the reaction, water and / or excess alcohol can be removed. Removal of water and alcohol can be carried out by all techniques known in the art, for example, by applying a gas stream and / or distillation, preferably distillation, more preferably under reduced pressure and / or high temperature, preferably both, and a preferred method is the use of apparatus such as a Dean-Stark trap.

[0062] In another embodiment, water and / or alcohol are removed using a gas stream, preferably using an inert gas such as nitrogen or argon, preferably nitrogen, or vapor made from water. In a more preferred embodiment, water and / or alcohol are removed by applying a vacuum and / or raising the temperature, most preferably using a device such as a Dean-Stark trap. Any removal of water and / or excess alcohol is carried out by applying a vacuum in the range of 0.1 mbar to 800 mbar, preferably 1 mbar to 500 mbar, more preferably 10 mbar to 100 mbar, and using high temperature.

[0063] In a preferred embodiment, during the reaction, an inert gas such as nitrogen or argon, preferably nitrogen vapor, is passed through the reaction mixture. This helps to keep the reaction mixture inert, but also helps to remove water produced from the chemical reaction and thus helps to control the amount of water present.

[0064] The molar ratio of amino acids to the hydroxyl groups of (optionally alkoxylated) alcohols is: (0.8 * n): 1~(1 * n): 1.5, and the number of hydroxyl groups in the (arbitrarily alkoxylated) alcohol is n.

[0065] In one embodiment, the method is carried out with a molar ratio of acid C to amino acid in the range of 0.8:1 to 1.2:1.

[0066] Suitable solvents for the reaction may include toluene, xylene, heptanol, and cyclohexene, and preferably, the reaction is carried out without a solvent.

[0067] In a preferred embodiment, the reaction is carried out without water in the presence of a minimum practical amount of water, preferably substantially water-free, most preferably water-free from the start of the reaction and for most of the time, more preferably water-free from the start until the reaction is essentially complete.

[0068] Such amino acids are obviously well known and can usually be prepared from natural sources. Others can be produced by modifying them, starting from natural sources, to obtain amino acids as starting materials. If such modification results in the addition of carbon atoms, for example by a chemical addition reaction, and such addition reaction uses non-fossil carbon atoms, the amino acids contain only non-fossil carbon. Therefore, it is preferable that only naturally occurring amino acids and / or naturally derived amino acids (not those produced by adding non-fossil carbon to building blocks to obtain such naturally derived amino acids) be used in the processes disclosed herein. More preferably, only naturally occurring amino acids are used.

[0069] The same applies to lactams; whenever lactams are available from natural sources, such natural or naturally occurring lactams are preferred, and naturally occurring lactams are even more preferred in order to increase the total non-fossil carbon content.

[0070] At least one alcohol having at least one hydroxyl group is selected from mono-, di-, and polyols, all of which may optionally be alkoxylated, the alkoxylation of at least one hydroxyl group being carried out in a step prior to step a), the alcohol being alkoxylated with at least one alkylene oxide, preferably at least 1 to 200, preferably 1 to 100, more preferably up to 50 moles per hydroxyl group, and in one embodiment even more preferably up to 20, for example up to 15, or even further up to 10 moles per hydroxyl group.

[0071] Alcohols containing one hydroxyl group are well known in the art. Similarly, alcohols containing at least two hydroxyl groups, provided by compound (A), are known to those skilled in the art. As described above, each alcohol may contain 1, 2, 3, 4, 5, or even more hydroxyl groups in its respective molecule / compound. Each alcohol may contain linear, branched, and / or cyclic alkyl fragments. Furthermore, each alcohol may contain aromatic fragments, as well as combinations of alkyl and aromatic fragments ("aralkyl" fragments). Furthermore, each alcohol may contain alkyl ether fragments. Examples of alcohols provided by compound (A) are glycerol, pentaerythritol, sorbitol, 1,1,1-trimethylolpropane (TMP), erythritol, or alkoxylated alcohols, such as polyethylene glycol.

[0072] Many alcohols derived from compound (A) of the present disclosure are commercially available, for example, from BASF SE under the trade names "Pluronic(s)" or "Pluriol" (e.g., as polyethylene glycol block(co)polymer).

[0073] The esteramine of the present invention and alcohol (A) for the method of the present invention are: (a) Nonalkoxylated linear C2-C36 alcohols such as monoalcohols including C1-C36 alkanols, for example, C6-C22 fatty alcohols, preferably C8-C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, and most preferably alcohol mixtures selected from C16 and C18 fatty alcohols; nonalkoxylated branched C3-C36 alcohols such as 2-ethylhexanol, 2-propylheptanol, isotridecanol, isononanol, and C9-C17 oxoalcohols; Alkoxylated linear C2-C36 alcohols such as alkoxylated mixtures of C6-C22 fatty alcohols, preferably alkoxylated mixtures of C8-C22 fatty alcohols, more preferably alkoxylated mixtures of C12-C14 fatty alcohols, and most preferably alkoxylated mixtures of C16-C18 fatty alcohols; Alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, alkoxylated C9-C17 oxoalcohols, and other alkoxylated branched C3-C36 alcohols; (b) Alkanediols, dialcohols such as polyalkoxylated C2-C6 alkanediols having at least two hydroxyl groups; (c) Sugar alcohols, oligo-alcohols such as polyalkoxylated C3-C6 alkanetriols having at least three hydroxyl groups; (d) Polyols such as C5-C6 alkane polyols and polyalkoxylated C5-C6 alkane polyols, polyglycerols, or polyetherols such as di- or tripentaerythritol, alkoxylated polyglycerols, alkoxylated di- or tripentaerythritol, and other alkoxylated polyetherols; (e) Phenoxyalkanols such as phenoxyethanol; Selected from, Alcohols selected from the group consisting of monoalcohols and alkoxylated di- and oligo-alcohols and alkoxylated polyols are preferred, and alcohols selected from the group consisting of monoalcohols and alkoxylated di-alcohols are more preferred.

[0074] In one embodiment of the present disclosure, at least one linear or branched C2-C chain containing at least one hydroxyl group is provided. 36 - An alcohol is used. In a preferred embodiment, at least one C8-C alcohol containing at least one hydroxyl group. 22 Fatty alcohols are used. In preferred embodiments, each containing at least one hydroxyl group, C16 , and C 18 A mixture of fatty alcohols is used. In another, more preferred embodiment, each containing at least one hydroxyl group, C 18 , and C 22 A mixture of fatty alcohols is used. In another, more preferred embodiment, at least one branched C9-C 17 Alcohols are used. In a more preferred embodiment, linear or branched C8-C2 compounds containing at least one hydroxyl group are used. 10 -A monoalcohol is used. In a more preferred embodiment, 2-propylheptanol or 2-ethylhexanol is used. In yet another more preferred embodiment, 2-ethylhexanol is used. In a more preferred embodiment of the present disclosure, at least one phenoxyalkanol is used. In yet another more preferred embodiment, phenoxyethanol is used.

[0075] Clearly, such alcohols are well known, and many of them come from natural sources. Others can be produced by modifying them, starting from natural sources. If such modification results in the addition of carbon atoms, for example, by a chemical addition reaction, and such addition reaction uses non-fossil carbon atoms, the alcohol contains only non-fossil carbon. Therefore, it is preferable to use only naturally occurring alcohols and / or naturally derived alcohols (not those produced by adding non-fossil carbon to building blocks to obtain such naturally derived alcohols) in the methods detailed herein. Even more preferably, only naturally occurring alcohols are used.

[0076] In a more preferred embodiment, the esteramine and the alcohol (A) used in the method of the present invention are alkoxylated alcohols. Such alkoxylated alcohols are typically, and preferably, obtained by alkoxyling at least one hydroxyl group of an alcohol previously defined herein with one or more alkylene oxides to produce an alkylene oxide chain comprising one or more portions derived from alkylene oxides selected from C2-C22 alkylene oxides, preferably C2-C4 alkylene oxides, wherein the alkylene oxide-derived portions may be arranged randomly, in blocks, or in multi-block order, or a combination thereof, preferably as blocks.

[0077] In one embodiment of the present disclosure, an alkyl alcohol is used that has been alkoxylated with only a single alkylene oxide. In a further embodiment, an alkyl alcohol is used that has been alkoxylated with a first alkylene oxide and then alkoxylated with a second alkylene oxide, thereby forming a block structure of different alkylene oxide blocks.

[0078] In the context of the details herein, if compound (A) comprises an alkoxylated alcohol, it comprises an alkoxylated fragment based on at least one C2-C22 alkylene oxide, preferably a C2-C4 alkylene oxide, more preferably ethylene oxide, and / or propylene oxide, most preferably each alcohol comprising at least one block based on ethylene oxide and / or propylene oxide, more preferably only one block consisting of ethylene oxide, or two blocks, where a first block (preferably an "inner block" directly bonded to the hydroxyl group of the alcohol) consists of ethylene oxide and a second block (preferably an "outer block" bonded to the "ethylene oxide block") consists of propylene oxide. More preferably, the EO block comprises 3-10 EO-derived moieties, and the PO block comprises 1-10 PO-derived moieties. Most preferably, only ethylene oxide is used.

[0079] Alkoxylation of alcohols can be achieved by carrying out an alkoxylation reaction using one alkylene oxide or more than one alkylene oxide. When more than one alkylene oxide is used, the resulting alkyl ether alcohol comprises randomly distributed alkylene oxide units, or a block of one alkylene oxide followed by another block of another alkylene oxide, or a block of one alkylene oxide followed by another block containing two or more alkylene oxides arranged in a random order, or a block containing two or more alkylene oxides followed by another block containing two or more alkylene oxides, each such block differing in the relative amount of their alkylene oxides, the arrangement of their alkylene oxides, and / or the identity of their alkylene oxides, so that two linked blocks differ in their chemical composition and / or arrangement, and such combinations of arrangements are possible in principle and are included in this disclosure.

[0080] In one embodiment disclosed herein, an alkyl alcohol is used that has been alkoxylated with only a single alkylene oxide. In a further embodiment, an alkyl alcohol is used that has been alkoxylated with a first alkylene oxide and then with a second alkylene oxide, thereby forming a block structure of different alkylene oxide blocks.

[0081] When switching from one block to the next, depending on how the alkoxylation reaction is carried out, there may be relatively small "regions" between blocks that are identical on all molecules of the alkoxylated monoalcohol, without a clear "boundary," and as a result, some "dirty" structures may exist. This clearly means that some very small amounts (e.g., one, or perhaps two or three) of the first type of alkylene oxide used can only be inserted after one or more of the second alkylene oxides have reacted, and this largely depends on the conversion rate achieved for the first alkylation reaction when some unreacted amounts of the first alkylene oxide are still present at the time the second alkylene oxide is added, i.e., when the second alkylene oxide is added.

[0082] Similarly, due to the statistical reaction of alkoxylation polymerization, the block length may differ slightly from one compound to the next, and thus it is clear that "alkoxylated monoalcohols" are actually mixtures of compounds having slightly different chain and block lengths.

[0083] This reaction can generally be carried out in the presence of a catalyst at a reaction temperature of about 70 to about 200°C, or in another embodiment, about 80 to about 160°C. The reaction can also be carried out at a pressure of up to about 10 bar, or in another embodiment, up to 8 bar.

[0084] Examples of suitable catalysts include alkali metal and alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide, and calcium hydroxide; alkali metal alkoxides, particularly sodium and potassium C1-C4 alkoxides such as sodium methoxide, sodium ethoxide, and potassium tert-butoxide; alkali metal and alkaline earth metal hydrides such as sodium hydride and calcium hydride; and alkali metal carbonates such as sodium carbonate and potassium carbonate. In one embodiment, alkali metal hydroxides are used. In another embodiment, potassium hydroxide and sodium hydroxide are used. Typical amounts of base used are alcohol and C2-C 22 The amount of alkylene oxide is preferably 0.01 to 10% by weight, or 0.05 to 2% by weight, based on the total amount of C2 to C4 alkylene oxides.

[0085] It should be noted that the alkylene oxides used to prepare alkoxylated alcohols may be derived from fossil carbon sources, non-fossil carbon sources, or mixtures thereof. Preferably, the amount of non-fossil carbon atoms in the alkylene oxide is at least 10%, at least 20%, at least 40%, at least 70%, at least 95%, and most preferably up to 100%, based on non-fossil carbon atoms, and the same applies to the entire compound of the present invention. Those skilled in the art are well aware of commercially available alkylene oxide products made from non-fossil carbon sources (these products are often marketed as “sustainable,” “renewable,” or “bio-based”). For example, Croda International (UK, Snaith) markets bioethanol-based ethylene oxide and related products under the “ECO”-Range. Furthermore, methods for preparing bio-based propylene oxide are also known (see Abraham, DS, "Production of propylene oxide from propylene glycol," Master's Thesis, University of Missouri-Columbia (2007) (p. 75)).

[0086] The esteramines of the present invention, and their salts, as well as the acid (C) for the method of the present invention, i) Sulfonic acids, for example, alkyl sulfonic acids, for example, methanesulfonic acid, ethylsulfonic acid, propylsulfonic acid, camphorsulfonic acid; alkylarylsulfonic acids, in particular alkylbenzenesulfonic acids, for example, toluenesulfonic acid (including mixtures thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (mixtures thereof), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid, and naphthalenesulfonic acid, and ii) An inorganic acid, selected from, for example, hydrochloric acid, hydrobromic acid, or phosphoric acid.

[0087] The acid used is preferably concentrated so as to minimize the amount of water introduced into the reaction, or it is used in solid form. Therefore, gases such as hydrogen chloride can also be used, as they can be introduced as gases. In one embodiment of the esteramine and method of the present invention, the acid is preferably selected from group i), more preferably p-toluenesulfonic acid and / or methanesulfonic acid, most preferably methanesulfonic acid.

[0088] In the case of the amount of water introduced into the reaction via the acid, the water can be removed before the orthoester is introduced by known means such as distillation procedures and apparatus (e.g., a Dean-Stark trap).

[0089] Esteramines are obtained in the form of cations, at least as partially protonated salts.

[0090] In a preferred embodiment, methanesulfonic acid is used as concentrated methanesulfonic acid. In another preferred embodiment, methanesulfonic acid is used as an aqueous solution of methanesulfonic acid at a concentration of about 70% by weight, or as a “pure” acid, for example, typically with a purity close to 100% by weight (equal to “about 100% by weight”). However, any concentration in between may also be used. In a further preferred embodiment, methanesulfonic acid is used as an aqueous solution of methanesulfonic acid at a concentration of about 70% by weight. However, in the most preferred embodiment, the sulfonic acid, for example, methanesulfonic acid, is introduced as a solid, and more preferably as a dry solid (to reduce the amount of water introduced into the reaction).

[0091] In one embodiment of the present disclosure, the entire amount of acid (C) is added at the start of the reaction. In another embodiment, the acid is added dropwise over a specific period during the reaction, under the condition that acid (C) is always present during the reaction.

[0092] This disclosure may also provide the esteramines of the present invention and their salts, starting from natural amino acids and / or natural alcohols, thus enabling the provision of products having high bio-based material content. Since alkylene oxides can also be derived from non-fossil sources, the compounds of the present invention may also be obtained containing only carbon atoms from non-fossil sources. Such products are in high demand by consumers and industry.

[0093] Processing composition: The processed compositions detailed herein comprise at least one fragrance raw material and an esteramine or a salt thereof, wherein the esteramine or salt thereof is preferably produced as described above. Processed compositions using esteramines and salts thereof obtained by the reaction processes detailed herein have less residual fatty alcohol (i.e., alcohol (A) as defined herein) compared with esteramines and salts thereof obtained by different reaction processes. Therefore, due to the lower amount of residual fatty alcohol in the processed compositions, the processed compositions have a better base odor. This can be confirmed by GC / MS (gas chromatography / mass spectrometry) headspace analysis comparing processed compositions that differ only in the source of the esteramines and salts used, which differ depending on the process from which they are derived.

[0094] The treatment composition may be a consumer product composition. The consumer product compositions of this disclosure may be useful in baby care, beauty care, fabric care, home care, family care, women's care, and / or healthcare applications. The treatment composition may be useful for treating surfaces such as fabrics, hair, or skin. The consumer product composition may be intended to be used or consumed in the manner in which it is sold. The consumer product composition may not be intended for subsequent commercial manufacture or modification.

[0095] The treatment composition may be a home care composition. The treatment composition may be a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition (such as shampoo or conditioner), a body cleansing composition, or a combination thereof.

[0096] The treatment composition may be a fabric care composition such as a laundry detergent composition (including a strong liquid detergent or unit-use article), a fabric conditioning composition (including a liquid fabric softening composition and / or a fabric strengthening composition), a laundry additive, a fabric pretreatment composition (including a spray, a pourable liquid, or a spray), a fabric refresher composition (including a spray), or a mixture thereof.

[0097] The processed composition may be a beauty care composition, for example, a hair treatment product (including shampoo and / or conditioner), a skin care product (including cream, lotion, or other topical application product for consumer use), a shaving care product (including shaving lotion, foam, or pre- or post-shaving treatment), a personal cleansing product (including liquid body wash, liquid hand soap, and / or bar soap), a deodorant and / or antiperspirant, or a mixture thereof.

[0098] The treatment composition may be a home care composition such as air care, car care, dishwashing, hard surface cleaning and / or treatment, and other cleaning for consumer or commercial use.

[0099] The processed composition may be in the form of a liquid composition, a granular composition, a hydrocolloid, a single-compartment pouch, a multi-compartment pouch, a soluble sheet, pastils or beads, a fibrous article, a tablet, a stick, a bar, a flake, a foam / mousse, a nonwoven sheet, or a mixture thereof.

[0100] The treatment composition may be in liquid form. The liquid composition may contain water in amounts ranging from about 30% by weight, or about 40% by weight, or about 50% by weight to about 99% by weight, or about 95% by weight, or about 90% by weight, or about 75% by weight, or about 70% by weight, or about 60% by weight of the composition. The liquid composition may be a liquid laundry detergent, a liquid fabric conditioner, a liquid dish soap, a hair shampoo, a hair conditioner, or a mixture thereof.

[0101] The treatment composition may be in solid form. The solid composition may be a powder composition or a granular composition. Such a composition may be agglomerated or spray-dried. Such a composition may contain a plurality of granules or particles, and at least a portion of such granules or particles may contain different compositions. The composition may be a powder cleaning composition or a granular cleaning composition, which may contain a bleaching agent. The composition may be in the form of beads or pastilles, which can be made from a liquid melt. The composition may be an extruded product.

[0102] The treatment composition may be in particulate form, such as multiple fine particles. Each fine particle may have a mass of about 1 mg to about 1 g. The emulsion may be dispersed in a water-soluble carrier. The water-soluble carrier may be selected from the group consisting of polyethylene glycol, sodium acetate, sodium bicarbonate, sodium chloride, sodium silicate, polypropylene glycol polyoxoalkylene, polyethylene glycol fatty acid ester, polyethylene glycol ether, sodium sulfate, starch, and mixtures thereof. The water-soluble carrier may be a water-soluble polymer. When the treatment composition is in particulate form, it may contain about 25% to about 99.99% by weight, or about 0.001% to about 50% by weight, of a water-soluble carrier of an esteramine or a salt thereof. The particulate form may be in the form of beads or pastilles.

[0103] The treatment composition may be in the form of a unit dose article such as a tablet, pouch, sheet or fibrous article. Such pouches typically include a water-soluble film that at least partially encloses the composition, such as a polyvinyl alcohol water-soluble film. Suitable films are available from MonoSol, LLC (Indiana, USA). The composition can be enclosed in a single-compartment pouch or a multi-compartment pouch. The multi-compartment pouch may have at least two, at least three, or at least four compartments. The multi-compartment pouch may include compartments arranged side by side and / or stacked. The composition contained in the pouch or its compartments may be a liquid, a solid (such as a powder), or a combination thereof. The pouch composition may have a relatively low amount of water, such as less than about 20% by weight, or less than about 15% by weight, or less than about 12% by weight, or less than about 10% by weight, or less than about 8% by weight of a detergent composition.

[0104] The treatment composition may be in the form of a spray and may be dispensed, for example, via a trigger sprayer and / or an aerosol container having a valve.

[0105] The treatment composition is 20 seconds -1 and at 21 °C, may have a viscosity of 1 to 1500 centipoise (1 to 1500 mPa * s), 100 to 1000 centipoise (100 to 1000 mPa * s), or 200 to 500 centipoise (200 to 500 mPa * s).

[0106] The treatment composition may contain an ester amine or a salt thereof produced by the method described herein, from about 0.001% to about 30% by weight, preferably from about 0.001% to about 20% by weight, more preferably from about 0.001% to about 15% by weight, 0.001% to about 10% by weight, more preferably from about 0.01% to about 5% by weight, more preferably from about 0.1% to about 3% by weight, more preferably from about 0.5% to about 2% by weight of the treatment composition.

[0107] The treatment composition according to the present invention may include a ratio of orthoester to esteramine or a salt thereof of about 1:20 to about 1:1, more preferably about 1:15 to about 1:5, more preferably about 1:12 to about 1:8, and more preferably about 1:10.

[0108] The treatment composition may contain orthoesters at a level of about 0.0001% to about 3% by weight, more preferably about 0.001% to about 0.5% by weight, more preferably about 0.01% to about 0.3% by weight, and even more preferably about 0.05% to about 0.2% by weight.

[0109] The treatment composition may contain at least one fragrance ingredient in an amount of about 0.001% to about 30% by weight, preferably about 0.001% to about 20% by weight, more preferably about 0.001% to about 15% by weight, 0.001% to about 10% by weight, more preferably about 0.01% to about 5% by weight, more preferably about 0.1% to about 3% by weight, and more preferably about 0.5% to about 2% by weight of the treatment composition.

[0110] At least one fragrance ingredient may include an aldehyde moiety, a ketone moiety, or a mixture thereof. As used herein, the term “Fragrance Ingredient” (or “PRM”) means a compound having a molecular weight of at least about 100 g / mol (sometimes up to about 1000 g / mol, preferably up to about 500 g / mol) that is useful for imparting odor, fragrance, essence, or scent, either alone or in combination with other fragrance ingredients. General lists of PRMs can be found in various references, such as “Perfume and Flavor Chemicals” Volumes I and II; Steffen Arctander Allured Pub.Co. (1994) and “Perfumes: Art, Science and Technology,” Miller, P.M. and Lamparsky, D., Blackie Academic and Professional (1994).

[0111] Fragrance raw materials containing aldehyde moieties are provided in Table B below. The materials provided in Table B are considered to be exemplary (but not limiting) examples of PRM suitable for use in this disclosure.

[0112] [Table 1-1]

[0113] [Table 1-2]

[0114] Fragrance raw materials that can be used in the processed compositions detailed herein may be selected from the group consisting of aldehyde-containing PRMs in Table A above. PRMs useful herein may contain an aldehyde moiety and may preferably be selected from the group consisting of: methylnonylacetaldehyde, benzaldehyde, floralozone, isocyclocitral, tripral (ligstral), presilchemon B, lilial, decylaldehyde, undecylenic acid aldehyde, cyclamen homoaldehyde, cyclamenaldehyde, dupical, onsidal, adoxal, melonal, calypsone, anisaldehyde, heliotropin, cuminaldehyde, centena Scentenal, 3,6-dimethylcyclohexa-3-ene-1-carbaldehyde, satenealdehyde, canthoxal, vanillin, ethyl vanillin, cinnamaldehyde, cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenal aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridral, butylcinnamaldehyde, limonelal, amylcinnamaldehyde, hexylcinnamaldehyde, citronellal, citral, cis-3-hexen-1-al, and mixtures thereof.

[0115] As described above, fragrance raw materials that may be useful in the processed compositions detailed herein may include ketone moieties. Fragrance raw materials containing ketone moieties are provided in Table C below. The materials provided in Table C are considered to be exemplary (but not limiting) examples of PRMs suitable for use according to this disclosure.

[0116] [Table 2-1]

[0117] [Table 2-2]

[0118] Fragrance raw materials that can be used in the processed compositions detailed herein may be selected from the group consisting of ketone-containing PRMs in Table C above. PRMs used herein may contain a ketone moiety and may preferably be selected from the group consisting of: nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalene-2-yleuthanone, nectaril, trimofix-O, fluramon, delta-damascone, β-damascone, α-damascone, methylionone, 2-hexylcyclopenta-2-en-1-one, galvascone, and mixtures thereof.

[0119] The processed compositions detailed herein may utilize fragrance raw materials selected from the group consisting of: methyl nonylacetaldehyde, benzaldehyde, floralozone, isocyclocitral, tripral (ligstral), presilchemon B, lilial, decylaldehyde, undecylenaldehyde, cyclamen homoaldehyde, cyclamenaldehyde, dupical, onsidal, adoxal, melonal, calypsone, anisaldehyde, heliotropin, cuminaldehyde, scentenal, 3,6-dimethylcyclohexa-3-en-1-carbaldehyde, satenealdehyde, canthoxal, vanillin, ethyl Vanillin, cinnamaldehyde, cis-4-decenal, trans-4-decenal, cis-7-decenal, undecylenate aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridral, butylcinnamaldehyde, limonel, amylcinnamaldehyde, hexylcinnamaldehyde Citronellal, citral, cis-3-hexen-1-al, nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalene-2-yleuthanone, nectaril, trimofix-O, fluramon, delta-damascone, β-damascone, α-damascone, methylionone, 2-hexylcyclopenta-2-en-1-one, galvascone, and mixtures thereof.

[0120] In the treatment compositions detailed herein, the fragrance raw materials used may preferably have an organic group in which the hydrophobic portion contains about 8 to about 18 chain atoms, more preferably about 10 to about 18 chain atoms, and preferably the chain atoms are carbon atoms. Such a chain length is considered to provide a degree of hydrophobicity suitable for promoting the deposition effect, particularly in laundry applications where the treatment composition described herein is an aqueous solution.

[0121] The fragrance ingredients used herein, including those listed above, can be obtained from a variety of suppliers, including International Flavors and Fragrances in New York, NY, USA; Givaudan in Vernier Switzerland; Firmenich in Geneva, Switzerland; Symrise in Holzminden, Germany; Kao in Tokyo, Japan; Takasago in Tokyo, Japan; and Florasynth in Tel-Aviv, Israel.

[0122] auxiliary ingredients The processing compositions disclosed herein, which may be consumer products, may include auxiliary materials. These auxiliary materials may provide benefits in the intended end use of the composition, or they may be processing aids and / or stabilizing aids.

[0123] Suitable auxiliary materials include surfactants, conditioning agents, adhesion aids, rheological modifiers or structuring agents, antioxidants, bleaching agents, stabilizers, builders, chelating agents, color transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymer dispersants, clays and stain removers / anti-redeposition agents, whitening agents, foam inhibitors, silicones, colorants, aesthetic dyes, undiluted (neat) fragrances, fragrance delivery systems (core / shell capsules, other pro-fragrance materials, etc.), structural elastochemicals, carriers, hydrotropes, processing aids, anti-aggregating agents, coatings, formaldehyde scavengers, and / or pigments.

[0124] Depending on the intended form, formulation, and / or end use, the compositions of the present disclosure may or may not contain one or more of the following auxiliary materials: surfactants, conditioning agents, adhesion aids, rheological modifiers or structuring agents, antioxidants, bleaching activators, surfactants, builders, chelating agents, color transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymer dispersants, clay and stain removers / anti-redeposition agents, whitening agents, foam inhibitors, dyes, additional fragrances and fragrance delivery systems, structural elastoides, fabric softeners, carriers, hydrotropes, processing aids, structuring agents, anti-aggregating agents, coatings, formaldehyde scavengers, and / or pigments.

[0125] The exact properties of these additional components and the concentrations in which they are incorporated depend on the physical form of the composition and the nature of the work performed. However, if one or more auxiliary agents are present, such one or more auxiliary agents may be present as detailed below. The following is a non-limiting list of suitable additional auxiliary agents.

[0126] A. Surfactants The treatment compositions disclosed herein may include surfactants. Surfactants may be useful, for example, to provide cleaning benefits. The compositions may include surfactant systems that may contain one or more surfactants.

[0127] The treatment compositions of the present disclosure may contain a surfactant system in an amount of about 0.1% to about 70% by weight, or about 2% to about 60% by weight, or about 5% to about 50% by weight of the composition. Liquid compositions may contain a surfactant system in an amount of about 5% to about 40% by weight of the composition. Compositions suitable for dense formulations, such as dense liquids, gels, and / or unit dose forms, may contain a surfactant system in an amount of about 25% to about 70% by weight, or about 30% to about 50% by weight of the composition.

[0128] The surfactant system may include anionic surfactants, nonionic surfactants, zwitterionic surfactants, cationic surfactants, amphoteric surfactants, or combinations thereof. The surfactant system may also include nonionic surfactants such as linear alkylbenzene sulfonates, alkyl ethoxylated sulfates, alkyl sulfates, and ethoxylated alcohols, amine oxides, or mixtures thereof. The surfactant may be derived at least in part from natural resources such as naturally sourced raw material alcohols.

[0129] Suitable anionic surfactants may include any conventional anionic surfactant, such as sulfate detergent surfactants for alkoxylated and / or non-alkoxylated alkyl sulfate materials, and / or sulfonic acid-based detergent surfactants, such as alkylbenzene sulfonates. Anionic surfactants may be linear, branched, or a combination thereof. Preferred surfactants include linear alkylbenzene sulfonates (LAS), alkyl ethoxylated sulfates (AES), alkyl sulfates (AS), or mixtures thereof. Other suitable anionic surfactants include branched modified alkylbenzene sulfonates (MLAS), methyl ester sulfonates (MES), sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), and / or alkyl ethoxylated carboxylates (AEC). Anionic surfactants may exist in acid form, salt form, or mixtures thereof. The anionic surfactant may be neutralized partially or entirely by, for example, an alkali metal (e.g., sodium) or an amine (e.g., monoethanolamine).

[0130] The surfactant system may include a nonionic surfactant. Suitable nonionic surfactants include alkoxylated aliphatic alcohols such as ethoxylated aliphatic alcohols. Other suitable nonionic surfactants include alkoxylated alkylphenols, alkylphenol condensates, medium-chain branched alcohols, medium-chain branched alkyl alkoxylates, alkyl polysaccharides (e.g., alkyl polyglycosides), polyhydroxy fatty acid amides, ether-capped poly(oxyalkylated) alcohol surfactants, and mixtures thereof. The alkoxylate units may be ethyleneoxy units, propyleneoxy units, or mixtures thereof. The nonionic surfactant may be linear, branched (e.g., medium-chain branched), or a combination thereof. Certain nonionic surfactants may include alcohols having an average of about 12 to about 16 carbons and an average of about 3 to about 9 ethoxy groups, such as a C12 - C14 EO7 nonionic surfactant.

[0131] Suitable zwitterionic surfactants include betaines such as alkyldimethylbetaine and coco dimethylamidopropyl betaine, C8 - C 18 (e.g., C 12 - C 18 ) amine oxides (e.g., C 12 - 14 dimethylamine oxide), and / or N-alkyl-N,N-dimethylamino-1-propane sulfonates (where the alkyl group may be C8 - C 18 or C 10 - C 14 ) and any conventional zwitterionic surfactants such as sulfobetaines and hydroxybetaines. The zwitterionic surfactant may include an amine oxide.

[0132] Depending on the formulation and / or intended end use, the composition may not substantially contain certain surfactants. For example, liquid fabric strengthening compositions such as fabric softeners may not substantially contain anionic surfactants because such surfactants can negatively interact with cationic components.

[0133] B. Conditioning Active Substances The processed compositions of the present disclosure may contain conditioning active substances. Compositions containing conditioning active substances may provide benefits relating to flexibility, wrinkle resistance, antistatic properties, conditioning, stretch resistance, color, and / or appearance.

[0134] The conditioning active substance may be present at a level of about 1% to about 99% by weight of the composition. The composition may contain a level of conditioning active substance ranging from about 1% by weight, or about 2% by weight, or about 3% by weight, up to about 99% by weight, or up to about 75% by weight, or up to about 50% by weight, or up to about 40% by weight, or up to about 35% by weight, or up to about 30% by weight, or up to about 25% by weight, or up to about 20% by weight, or up to about 15% by weight, or up to about 10% by weight of the composition. The composition may contain a level of conditioning active substance ranging from about 5% to about 30% by weight of the composition.

[0135] Suitable conditioning active substances for the compositions of this disclosure include quaternary ammonium ester compounds, silicones, non-esterified quaternary ammonium compounds, amines, fatty acid esters, sucrose esters, silicones, dispersible polyolefins, polysaccharides, fatty acids, softening or conditioning oils, polymer latexes, polyhydroxystearic acid and / or its derivatives, glyceride copolymers, or combinations thereof. Preferably, the conditioning active substance is a cationic conditioning active substance that can improve the delivery / deposition of esteramines or salts thereof.

[0136] The treatment composition may contain a conditioning active substance, which includes a quaternary ammonium ester compound. Preferably, the quaternary ammonium ester compound is present in a concentration of about 2% to about 35% by weight, preferably about 4% to about 25% by weight, more preferably about 5% to about 20% by weight, even more preferably about 6% to about 15% by weight, and even more preferably about 7% to about 12% by weight of the treatment composition. The quaternary ammonium ester compound (also known as "quaternary ester ammonium") may be a monoester quaternary ammonium, a diester quaternary ammonium, a triester quaternary ammonium, or a combination thereof. Preferably, the diester quaternary ammonium material forms the main portion (whether majority or plural) of the ester quaternary ammonium compound. In addition to providing a conditioning effect, it is believed that by selecting an appropriate type and / or level of conditioning active substance (i.e., a quaternary ammonium ester compound), the deposition and / or performance of the esteramine or salt thereof described herein can be improved.

[0137] Quaternary ammonium ester compounds may include compounds with the following formula: {R 2 (4-m) -N+-[XYR 1 ] m}A - m is 1, 2, or 3, provided that in a given numerator, each value of m is the same. Each R may contain 13 to 22 carbon atoms. 1 These are independently linear hydrocarbyl groups or branched hydrocarbyl groups, preferably R 1 It is linear, and more preferably R 1 It is a partially unsaturated linear alkyl chain, Each R 2 R is independently a C1-C3 alkyl group or a hydroxyalkyl group, and / or each R 2This is selected from methyl, ethyl, propyl, hydroxyethyl, 2-hydroxypropyl, 1-methyl-2-hydroxyethyl, poly(C2-C3 alkoxy), polyethoxy, benzyl, and more preferably methyl or hydroxyethyl. Each X is independently -(CH2)n-, -CH2-CH(CH3)-, or -CH(CH3)-CH2-, and each n is independently 1, 2, 3, or 4, preferably each n is 2. Each Y is independently -O-(O)C- or -C(O)-O-, A- is independently selected from the group consisting of chlorides, bromides, methyl sulfate, ethyl sulfate, sulfuric acid, and nitric acid, preferably A- is selected from the group consisting of chlorides and methyl sulfate, and more preferably A- is methyl sulfate.

[0138] For monoester quaternary ammonium compounds, m is 1. For diester quaternary ammonium compounds, m is 2. For triester quaternary ammonium compounds, m is 3. The conditioning active substance may include a mixture of monoester quaternary ammonium compounds and diester quaternary ammonium compounds, or further a mixture of monoester quaternary ammonium compounds, diester quaternary ammonium compounds, and triester quaternary ammonium compounds. As will be understood by those skilled in the art, the mixture may depend in part on starting / supply materials such as dialkanolamines or tryalkanolamines.

[0139] Quaternary ammonium ester compounds can be derived from fatty acids characterized by having an iodine value of 0 to 140, or 0 to about 90, or about 10 to about 70, or about 15 to about 50, or about 18 to about 30. The iodine value can be determined according to the method provided in U.S. Patent Application Publication No. 2020 / 0407665 (corresponding to International Publication No. 2020 / 264566).

[0140] This composition may contain a quaternary ammonium ester compound, a silicone, or a combination of several sets thereof, preferably one set. The total amount of the quaternary ammonium ester compound and the silicone may be about 5% to about 70% by weight of the composition, or about 6% to about 50% by weight, or about 7% to about 40% by weight, or about 10% to about 30% by weight, or about 15% to about 25% by weight. The composition may contain the quaternary ammonium ester compound and the silicone in a weight ratio of about 1:10 to about 10:1, or about 1:5 to about 5:1, or about 1:3 to about 1:3, or about 1:2 to about 2:1, or about 1:1.5 to about 1.5:1, or about 1:1.

[0141] The composition may contain a mixture of different types of conditioning active substances. The composition of this disclosure may contain a specific conditioning active substance, but may not substantially contain other conditioning active substances. For example, the composition may not contain a quaternary ammonium ester compound, a silicone, or both. The composition may contain a quaternary ammonium ester compound, but may not substantially contain a silicone. The composition may contain a silicone, but may not substantially contain a quaternary ammonium ester compound.

[0142] The conditioning active substance may include a glyceride copolymer. The glyceride copolymer may be derived from natural oils. Examples of natural oils, but not limited to these, include vegetable oils, algal oils, fish oils, animal fats, tall oils, derivatives of these oils, and any combination of these oils. Typical non-limiting examples of vegetable oils include low-erucic acid rapeseed oil (canola oil), high-erucic acid rapeseed oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, linseed oil, palm kernel oil, tuna oil, jatropha oil, mustard oil, pennycress oil, camelina oil, hemp seed oil, and castor oil, preferably canola oil. Typical non-limiting examples of animal fats include lard, animal fat, poultry oil, yellow fat, and fish oil. Tall oil is a by-product of wood pulp production. The glyceride copolymer may also be a metallated unsaturated polyol ester.

[0143] C. Adhesion aids The processed compositions of the present disclosure may include adhesion aids. Adhesion aids may promote the deposition of various beneficial agents, including esteramines or salts thereof, conditioning active substances, fragrances, or fragrance delivery systems (e.g., encapsulated fragrances), or combinations thereof, thereby improving the performance benefits of the composition and / or enabling a more efficient formulation of such beneficial agents. The composition may contain 0.0001% to 3% by weight, preferably 0.0005% to 2% by weight, more preferably 0.001% to 1% by weight, or about 0.01% to about 0.5% by weight, or about 0.05% to about 0.3% by weight of the adhesion aid. The adhesion aid may be a cationic or amphoteric polymer, preferably a cationic polymer.

[0144] Cationic polymers in general and methods for producing them are well known in the literature. Suitable cationic polymers include quaternary ammonium polymers known as "polyquaternium" polymers, named in the International Nomenclature for Cosmetic Ingredients, such as polyquaternium-6 (poly(diallyldimethylammonium chloride)), polyquaternium-7 (a copolymer of acrylamide and diallyldimethylammonium chloride), polyquaternium-10 (quaternized hydroxyethylcellulose), and polyquaternium-22 (a copolymer of acrylic acid and diallyldimethylammonium chloride).

[0145] The adhesion aid may be selected from the group consisting of polyvinylformamide, partially hydroxylated polyvinylformamide, polyvinylamine, polyethyleneimine, ethoxylated polyethyleneimine, polyvinyl alcohol, polyacrylate, and combinations thereof.

[0146] The cationic polymer may include cationic acrylates and / or cationic methacrylates. Such polymers may also be copolymers further comprising nonionic monomers, such as acrylamide. The cationic polymer may be linear or crosslinked. The adhesion aid may include a combination of linear cationic polymers and crosslinked cationic polymers.

[0147] Adhesion aids may be added to the consumer product composition simultaneously with the delivery particles (for example, simultaneously with encapsulated beneficial agents such as encapsulated perfumes) or directly / independently. The weight-average molecular weight of the polymer may be 500 to 5,000,000 daltons, or 1,000 to 2,000,000 daltons, or 2,500 to 1,500,000 daltons, when measured by size exclusion chromatography against a polyethylene oxide standard using refractive index (RI) detection. The weight-average molecular weight of the cationic polymer may be 5,000 to 37,500 daltons.

[0148] D. Further fragrances and / or fragrance delivery systems The processed compositions of this disclosure may include further fragrances and / or fragrance delivery systems.

[0149] The processed compositions of this disclosure may also contain other fragrance ingredients, including PRMs that do not contain aldehyde or ketone moieties, for example, in an undiluted or free form. For example, other PRMs may be provided in the processed composition undiluted or as free oils, even if they do not bind to esteramines or salts thereof. Such mixtures may be desirable, for example, to provide a more appropriate olfactory experience.

[0150] The processed compositions of the present disclosure may further contain undiluted fragrance, preferably undiluted fragrance raw materials that do not contain aldehydes or ketone moieties. Preferably, the undiluted fragrance includes alcohol-containing fragrance raw materials. Suitable alcohol-containing fragrance raw materials are known to those skilled in the art and may include geraniol, citronellol, cinnamon alcohol, eugenol, etc. However, the undiluted fragrance may further contain free fragrance raw materials that include aldehydes and / or ketone moieties.

[0151] The processed compositions of the Disclosure may additionally or alternatively include a fragrance delivery system. Such a fragrance delivery system may take the form of a polymer-assisted delivery system. Such a fragrance delivery system may take the form of an encapsulation, for example, a core-shell encapsulation, in which the core contains a fragrance raw material and is surrounded by a polymer shell. The polymer shell may include polymer materials derived from polyacrylates, polyureas, polyurethanes, polysaccharides, polyvinyl alcohols, melamines, derivatives thereof, or combinations thereof. Additionally or alternatively, suitable fragrance delivery systems may include known pro-fragrance materials.

[0152] Other materials The treatment compositions and / or premix compositions of the present disclosure may include unreacted reactants and / or decomposition products of the esteramines or salts thereof described herein. For example, the treatment compositions and / or premix compositions of the present disclosure may include precursors or derivatives of carbon-containing cores alone, such as parent amino acids (e.g., H2-AH, where A is substantially as defined above according to Formula III, and G = oxygen), hydrophobic modified amino acids (e.g., H2-AQ, where A is substantially as defined above according to Formula III), free forms of hydrophobic substances (e.g., HGQ such as fatty alcohols like dodecanol), forms of esteramines or salts thereof that do not contain hydrophobic substances (e.g., ZAH, where A is substantially as defined above according to Formula III, and G = oxygen), free beneficial agents, such as aldehyde or ketone-containing PRMs, or combinations thereof.

[0153] Method for manufacturing the processed composition This disclosure relates to a manufacturing process for any of the compositions described herein. A manufacturing process for a processed composition, which may be a consumer product, may include a step of combining at least one fragrance raw material and an esteramine or salt thereof as described herein with an auxiliary material as described herein.

[0154] At least one fragrance ingredient and / or a compound of an esteramine or a salt thereof may be combined with such auxiliary materials by means of mixing and / or spraying.

[0155] The compositions of this disclosure can be formulated into any preferred form and prepared by any process selected by the compounder. At least one fragrance ingredient, an esteramine or a salt thereof, and auxiliary materials can be combined in batch processes, recirculating loop processes, and / or in-line mixing processes. Suitable equipment for use in the methods disclosed herein includes continuous agitated tank reactors, homogenizers, turbine agitators, recirculating pumps, paddle mixers, high-shear mixers, static mixers, plow shear mixers, ribbon blenders, vertical shaft granulators and drum mixers (both batch-type and, where available, in continuous process configurations), spray dryers, and extruders.

[0156] For example, a method for producing a processed composition may include the step of combining at least one fragrance raw material and an esteramine or salt thereof according to the present disclosure with a base composition, preferably a liquid base composition, wherein the base composition includes auxiliary components. This process can be carried out, for example, by a batch process or an in-line mixing process, preferably an in-line mixing process.

[0157] A method for producing a processed composition may include, as described herein, the steps of combining at least one fragrance raw material and / or an esteramine or a salt thereof, a beneficial agent, and an auxiliary component. Preferably, the auxiliary component is part of the base composition, and at least one fragrance raw material, an esteramine or a salt thereof, and / or a beneficial agent are each added to the base composition as separate inputs. The separate inputs may be added sequentially (e.g., consecutively) or substantially simultaneously. Preferably, the base composition is a liquid. This process can be carried out, for example, in a batch process or an in-line mixing process, preferably an in-line mixing process.

[0158] The method for producing the treatment composition may include the step of adding a premix to a base composition. The premix composition may contain at least one fragrance ingredient, an esteramine or a salt thereof, and / or a beneficial agent, as described herein. The premix composition may be obtained by combining at least one fragrance ingredient, and / or an esteramine or a salt thereof, with a beneficial agent, as described herein. The premix composition may contain at least one fragrance ingredient and an esteramine or a salt thereof according to this disclosure, for example, by the reaction of an esteramine or a salt thereof with a beneficial agent. The premix may optionally contain water. This process can be carried out, for example, by a batch process or an in-line mixing process, preferably an in-line mixing process. The premix may be in solid form, such as a PEG-based pastille, or may be particularly preferred when producing a treatment composition that becomes solid. In such cases, the removal or reduction of water from the premix may be useful, for example, via a water scavenger such as magnesium sulfate, or by the use of molecular sieves or distillation in a vacuum.

[0159] Surface treatment method This disclosure further relates to a method for treating a surface (e.g., the surface of an article) with a treatment composition according to this disclosure. Such a method may provide benefits relating to cleaning, conditioning, hygiene, and / or cooling effects.

[0160] Suitable surfaces include fabrics (including clothing, towels, or linens), hard surfaces (such as tiles, porcelain, linoleum, or wooden floors), tableware, hair, skin, or mixtures thereof.

[0161] The method may include a step of bringing an article or surface into contact with a treatment composition of the Disclosure, optionally in the presence of water, and optionally further including a step of rinsing and / or drying the article or surface. The treatment composition may be in an undiluted form or may be diluted with a liquid, such as a cleaning solution or a rinsing solution. The treatment composition may be diluted with water before, during, or after contact with the surface or article. The surface or article may be optionally washed and / or rinsed before and / or after the contact step.

[0162] A method for treating and / or cleaning a surface may include the following steps:

[0163] a) Optionally, a step of cleaning, rinsing, and / or drying the surface. b) A step of bringing the surface into contact with the treatment composition described herein, optionally in the presence of water. c) Optionally, a step of cleaning and / or rinsing the surface, d) A step of drying by passively drying and / or by an active method such as a washing machine or dryer.

[0164] For the purposes of this disclosure, cleaning includes, but is not limited to, scrubbing and mechanical agitation. Fabrics may include most fabrics that can be washed or treated under normal consumer or industrial use conditions.

[0165] Liquids containing the disclosed compositions may have a pH of about 3 to about 11.5. When diluted, such compositions are typically used in solution at concentrations of about 500 ppm to about 15,000 ppm. If the washing solvent is water, the water temperature is typically in the range of about 5°C to about 90°C, and if the surface is part of a fabric, the weight ratio of water to fabric is typically about 1:1 to about 30:1.

[0166] This disclosure further discloses a method for treating a surface or article, preferably a fabric, with an aqueous treatment solution comprising an orthoester, at least one fragrance ingredient, and an esteramine or a salt thereof according to this disclosure. The method may include a step of bringing the surface or article, preferably a fabric, into contact with the aqueous solution. The esteramine or a salt thereof may be present in the aqueous solution at a level of about 0.001 ppm (e.g., 1 ppb) to about 1000 ppm by weight.

[0167] This disclosure further discloses a method for treating a surface or article, preferably a fabric, with an aqueous treatment solution comprising an orthoester, at least one fragrance ingredient, and / or an esteramine or a salt thereof according to this disclosure. The method may include a step of bringing the surface or article, preferably a fabric, into contact with the aqueous solution. The esteramine or a salt thereof may be present in the aqueous solution at a level of about 0.001 ppm (e.g., 1 ppb) to about 1000 ppm by weight.

[0168] use This disclosure relates to the use of the treatment compositions described herein to provide the benefit of freshness.

[0169] This disclosure relates to the use of the treatment compositions described herein for providing an anti-odor effect.

[0170] combination The specific combinations contemplated in this disclosure are described in the following alphabetically designated sections herein. These combinations are for illustrative purposes only and are not intended to limit the scope of this disclosure.

[0171] A. A processed composition comprising at least one fragrance raw material and an esteramine of formula (I) or a salt thereof,

[0172] [ka] During the ceremony, they act independently of each other. t is an integer between 1 and 100; A1 is independently selected for each repeating unit t from the list consisting of ethyleneoxy group, 1,2-propyleneoxy group, 1,2-butyleneoxy group, 2,3-butyleneoxy group, i-butyleneoxy group, pentyleneoxy group, hexyleneoxy group, styryloxy group, decenyloxy group, dodecenyloxy group, tetradecenyloxy group, and hexadecanyloxy group, and when t is equal to 1, the oxygen atom of the A1 group is bonded to the B group, and the next A1 group is always bonded to the previous A1 group via an oxygen atom; B1 is linked to each other independently, forming a linear chain C1~C 12 Alkanediyl group, and branched C1-C 12 Selected from the group consisting of alkanediyl groups; R4, R8, and R 12 This is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; However, Z1 is alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and compounds according to formula (II):

[0173] [ka] [In the formula, they are independent of each other, w is an integer between 0 and 12; R 13 and R 14 Each repeating unit w is independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; R 15 , R 16 , R 17 , and R 18 [Selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl] A compound is selected from the group consisting of the following, and the compound according to formula (II) is * The compound is linked to the compound of formula (I) via a bond labeled with R4, R8, and / or R12 A treatment composition in which at least one of the groups contains at least seven or more carbon atoms.

[0174] B. The treatment composition according to paragraph A, comprising a salt of an esteramine, wherein the salt is formed by at least partial protonation of the amine group with an acid that is a protic organic acid or a protic inorganic acid.

[0175] C. The treated composition according to any one of paragraphs A to B, wherein the salt is formed by at least partial protonation of an amine group with an acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, and lactic acid.

[0176] D.A1 is a processed composition according to any one of paragraphs A to C, in which D.A1 is independently selected for each repeating unit t from a list consisting of an ethyleneoxy group, a 1,2-propyleneoxy group, and a 1,2-butyleneoxy group.

[0177] E.Z1 is selected from the group consisting of alanine, glycine, lysine, and compounds according to formula (II), where w is an integer in the range of 1 to 4, and the compounds according to formula (II) are * The compound is linked to the compound of formula (I) via a bond labeled with, provided that at least one group R4, R8, and / or R 12 The treatment composition according to any one of paragraphs A to D, which contains at least seven carbon atoms.

[0178] F. A processed composition comprising at least one fragrance raw material and an esteramine or salt thereof obtained by a method using a catalytic amount of at least one orthoester, wherein the method is: a) i) α-, β-, γ-, δ-, ε-amino acids such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamate, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine; sarcosine, N, At least one amino acid selected from α-amino acids having a secondary or tertiary amino group, such as N-dimethylglycine; other amino acids such as 6-aminohexanoic acid, 4-aminobutanoic acid, 3-aminopropanoic acid, 12-aminododecanoic acid, 11-aminoundecanoic acid; and amino acids formally derived from hydrolysis, such as α-lactam (3 ring atoms), β-lactam (4 ring atoms), γ-lactam (5 ring atoms), etc., wherein such lactams are preferably β-propiolactam, γ-butyrolactam, δ-valerolactam, γ-valerolactam ii) at least one amino acid, which is e-caprolactam, d-decalactam, g-decalactam, e-decalactam; preferably alanine, valine, β-alanine, 6-aminohexanoic acid; ii) at least one alcohol (A) having at least one hydroxyl group, selected from mono-, di-, and polyols, all of which may optionally be alkoxylated, the alkoxylation of at least one hydroxyl group carried out in a step prior to step a), and the alcohol has at least one alkyl group per hydroxyl group iii) at least one alcohol (A) alkoxylated with an alkylene oxide, preferably at least 1 and up to 200, preferably 1 to 100, more preferably up to 50 moles, and iii) at least one acid (C) selected from inorganic and organic acids, wherein the organic or inorganic acid preferably has a pKa value in the range of -3 to +5, more preferably -2.5 to 1.5, preferably at least one organic acid such as a sulfonic acid, more preferably an alkyl sulfonic acid and / or an aryl sulfonic acid. In the presence of; iv) In the presence of at least one orthoester such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, A step to obtain an esteramine salt by the reaction, A treatment composition comprising: b) a step of producing an esteramine salt, wherein the orthoester is used in less than a stoichiometric amount, preferably a catalytic amount (relative to the amino acid), and the alcohol used for esterification is different from the alcohol residue in the orthoester; b) optionally a step of neutralizing the obtained esteramine salt with at least one base to obtain a free esteramine.

[0179] G. The treatment composition described in paragraph F, wherein alcohol (A) is: a. Non-alkoxylated linear C2-C36 alcohols such as a monoalcohol such as C1-C36 alkanols, preferably a mixture of alcohols selected from C6-C22 fatty alcohols, more preferably C8-C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, and most preferably C16 and C18 fatty alcohols; non-alkoxylated branched C3-C36 alcohols such as 2-ethylhexanol, 2-propylheptanol, isotridecanol, isononanol, C9-C17 oxoalcohols Alkoxylated linear C2-C36 alcohols such as alkoxylated mixtures of C6-C22 fatty alcohols, preferably alkoxylated mixtures of C8-C22 fatty alcohols, more preferably alkoxylated mixtures of C12-C14 fatty alcohols, most preferably alkoxylated mixtures of C16-C18 fatty alcohols; alkoxylated branched C3-C36 alcohols such as alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, alkoxylated C9-C17 oxoalcohols, A monoalcohol selected from the group; A treatment composition selected from b. dialcohols such as alkanediols and polyalkoxylated C2-C6 alkanediols having at least two hydroxyl groups; c. oligoalcohols such as polyalkoxylated C3-C6 alkanetriols having at least three hydroxyl groups; d. polyols such as sugar alcohols, polyalkoxylated C5-C6 alkanepolyols, diglycerols, triglycerol polyglycerols, dipentaerythritol, tripentaerythritol, and other glycerols; and / or e. phenoxyalkanols such as phenoxyethanol, wherein alcohols selected from the group of monoalcohols and alkoxylated di-, oligo-alcohols and alkoxylated polyols are preferred, and alcohols selected from the group of monoalcohols and alkoxylated di-alcohols are more preferred.

[0180] H. A treatment composition according to any one of paragraphs F to G, wherein the alcohol (A) used is an alkoxylated alcohol obtained by alkoxyling at least one hydroxyl group of the alcohol according to claim 2 with one or more alkylene oxides to produce an alkylene oxide chain comprising one or more portions derived from C2-C22 alkylene oxides, preferably selected from C2-C4 alkylene oxides, wherein the alkylene oxide-derived portions may be arranged randomly, in blocks, or in multi-block order, or in combination thereof, preferably as blocks, and more preferably containing only one block consisting of ethylene oxide, or consisting of two blocks in which a first block (preferably an "inner block" directly bonded to the hydroxyl group of the alcohol) consists of ethylene oxide and a second block (preferably an "outer block" bonded to the ethylene oxide block) consists of propylene oxide, wherein such a diblock more preferably consists of 3 to 10 EO-derived portions, and a PO block consists of 1 to 10 PO-derived portions.

[0181] I. A treatment composition according to any one of paragraphs F to H, wherein the acid (C) is i) an alkyl sulfonic acid such as methanesulfonic acid, ethylsulfonic acid, propylsulfonic acid, and camphorsulfonic acid; an alkylaryl sulfonic acid such as toluenesulfonic acid (including a mixture thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (a mixture of isomers), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid, and naphthalenesulfonic acid; specifically, an alkylbenzenesulfonic acid, preferably p-toluenesulfonic acid and methanesulfonic acid, more preferably methanesulfonic acid; ii) Inorganic acids such as hydrochloric acid, hydrobromic acid, and phosphoric acid; Selected from, Preferably, a treatment composition selected from group i).

[0182] J. Acid (C) is selected so that the esteramine is obtained as a salt in cationic form, preferably the selected acid is methanesulfonic acid, and the resulting esteramine is a salt in cationic form, according to any one of paragraphs F to I.

[0183] K. A treatment composition according to any one of paragraphs F to J, wherein the molar ratio of amino acids to hydroxyl groups of an (optionally alkoxylated) alcohol is (0.8 × n):1 to (1 × n):1.5, and the number of hydroxyl groups of the (optionally alkoxylated) alcohol is n.

[0184] L. The method is carried out with a molar ratio of acid (C) to amino acid in the range of 0.8:1 to 1:1.2, and is the treatment composition described in any one of paragraphs F to K.

[0185] A treatment composition according to any one of paragraphs F to L, wherein the reaction is carried out at a temperature of 120°C to 150°C, such as 50 to 200°C, preferably 70 to 180°C, more preferably 80 to 160°C, most preferably 60, 65, 75, 85, 90, 95, 100, 110, 115, 120, 125, 130, 135, 140, 145, 155, 165, 170, 190°C, etc.; b. for 1 to 30 hours, preferably from 2 hours, more preferably from 3 hours, even more preferably at least 5 hours, preferably up to 48 hours, more preferably up to 20 hours, even more preferably c. A processed composition carried out over a period of time up to 15 hours, preferably 3 to 24 hours, more preferably 5 to 24 hours, most preferably 10 to 24 hours, etc.; c. A pressure of 0.001 to 10 bar, more preferably 1 to 5 bar, more preferably 1 to 4 bar, etc., or 0.001 to 10 bar, such as 0.001 bar, more preferably 0.005 bar, even more preferably 0.1 bar, preferably up to 8 bar, more preferably up to 5 bar, even more preferably up to 4 bar, etc., or 0.001 to 10 bar, such as 1 to 1000 mbar, more preferably 100 to 500 mbar, etc.

[0186] N. The treatment composition according to any one of paragraphs F to M, wherein the solvent for the reaction is selected from water, toluene, xylene, heptanol, cyclohexene, etc., and preferably water alone.

[0187] O. A processed composition according to any one of paragraphs F to N, wherein water and / or excess alcohol are removed during or after the reaction, preferably at least during the reaction, and such removal is carried out preferably by applying a gas stream using an inert gas such as nitrogen or argon, preferably a gas such as vapor made from nitrogen or water, preferably by applying a gas stream using an inert gas, more preferably nitrogen, and / or by distillation, preferably by distillation, more preferably by distillation under reduced pressure and / or by distillation at high temperature, preferably both, a more preferred method being the use of an apparatus such as a Dean-Stark trap, most preferably using a Dean-Stark trap, and such removal is carried out more preferably by applying a vacuum in the range of 0.1 mbar to 800 mbar, preferably 1 mbar to 500 mbar, more preferably 10 mbar to 100 mbar and using high temperature.

[0188] A treatment composition according to any one of paragraphs A to O of P., wherein the treatment composition is a consumer product, preferably selected from a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition, a body cleansing composition, or a mixture thereof.

[0189] Q. The treatment composition is the treatment composition according to any one of paragraphs A to P, further comprising a beneficial agent.

[0190] R. The beneficial agent is selected from antimicrobial agents, insecticides, insecticides, antifungal agents, herbicides, color dyes, antioxidants, non-fragrance functional substances, or combinations thereof, as described in any one of paragraphs A to Q of the treatment composition.

[0191] S. At least one fragrance raw material is selected from the group consisting of the following, and is part of the treatment composition described in any one of paragraphs A to R: methyl nonylacetaldehyde, benzaldehyde, floralozone, isocyclocitral, tripral (ligstral), presilchemon B, lilial, decylaldehyde, undecylenic acid aldehyde, cyclamen homoaldehyde, cyclamen aldehyde, dupical (dup ical), Onsidal, Adoxal, Melonal, Calypsone, Anisaldehyde, Heliotropin, Cuminaldehyde, Scentenal, 3,6-Dimethylcyclohexa-3-ene-1-carbaldehyde, Satinaldehyde, Canthoxal, Vanillin, Ethyl Vanillin, Cinnamaldehyde, Cith-4-decenal, Trans-4-decenal, Cith-7-decenal Senal, undecylenate aldehyde, trans-2-hexenal, trans-2-octenal, 2-undecenal, 2,4-dodecadienal, cis-4-heptenal, floridral, butylcinnamaldehyde, limonelal, amylcinnamaldehyde, hexylcinnamaldehyde, citronellal, citral, cis-3-hexen-1-al, nerolion, 4-(4-methoxyphenyl)butan-2-one, 1-naphthalene-2- A fragrance raw material selected from the group consisting of yleuthanone, nectaril, trimofix O, fluramon, delta-damascone, β-damascone, α-damascone, methyl ionone, 2-hexylcyclopenta-2-en-1-one, galvascone, and mixtures thereof, wherein the hydrophobic portion is an organic group containing about 8 to about 18 chain atoms, preferably the chain atoms being carbon atoms, as described in any one of paragraphs A to K.

[0192] T. A processed composition according to any one of paragraphs A to S, wherein at least one fragrance ingredient contains an aldehyde moiety.

[0193] U. A treatment composition according to any one of paragraphs A to T, wherein the treatment composition further comprises auxiliary components comprising one or more of the following: surfactants, conditioning active substances, adhesion aids, rheological modifiers or structuring agents, acid fasteners, bleaching agents, stabilizers, builders, chelating agents, color transfer inhibitors, dispersants, enzymes, enzyme stabilizers, catalytic metal complexes, polymer dispersants, mud and stain removers / redeposition inhibitors, whitening agents, foam inhibitors, silicones, colorants, aesthetic dyes, undiluted fragrances, fragrance delivery systems, structural elastochemicals, carriers, hydrotropes, processing aids, anti-aggregating agents, coatings, formaldehyde scavengers, and / or pigments.

[0194] V. The treatment composition according to any one of paragraphs A to U, wherein the auxiliary component comprises a conditioning active substance, preferably the conditioning active substance comprises a quaternary ammonium ester compound, and more preferably the quaternary ammonium ester compound is present in a concentration of about 2% to about 35% by weight, preferably about 4% to about 25% by weight, more preferably about 5% to about 20% by weight, preferably about 6% to about 15% by weight, and more preferably about 7% to about 12% by weight of the treatment composition.

[0195] W. The treatment composition is a liquid composition, a granular composition, a hydrophilic colloid, a single-compartment pouch, a multi-compartment pouch, a soluble sheet, pastil or beads, a fibrous article, a tablet, a stick, a bar, a flake, a foam or mousse, a nonwoven fabric, or a mixture thereof, preferably a liquid composition, as described in any one of paragraphs A to V.

[0196] The treatment composition according to any one of paragraphs A to W, wherein X. esteramine or a salt thereof is present in the treatment composition at a level of about 0.001% to about 30% by weight, more preferably about 0.01% to about 5% by weight, more preferably about 0.1% to about 3% by weight, and even more preferably about 0.5% to about 2% by weight.

[0197] Y. The processed composition according to any one of paragraphs A to X, wherein at least one fragrance ingredient is present in the processed composition at a level of about 0.001% to about 30% by weight, more preferably about 0.01% to about 5% by weight, more preferably about 0.1% to about 3% by weight, and even more preferably about 0.5% to about 2% by weight.

[0198] Z. A method for treating an article or surface, optionally comprising treating the article or surface with a treatment composition described in any one of paragraphs A to Y, in the presence of water.

[0199] The dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​listed. Instead, unless otherwise specified, each such dimension is intended to mean both the listed value and the functionally equivalent range encompassing that value. For example, a dimension disclosed as "40 mm" is intended to mean "approximately 40 mm."

[0200] All documents referenced herein, including any patents or patent applications that are cross-referenced or related, and any patent applications or patents on which this application claims priority or benefit thereof, are incorporated herein by reference in their entirety, unless expressly excluded or otherwise limited. No citation of any document shall be deemed prior art to any invention disclosed or claimed herein, nor shall it be deemed to teach, suggest or disclose any such invention, either alone or in combination with any one or more other references. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in any document incorporated by reference, the meaning or definition given to that term in this document shall prevail.

[0201] While specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. Therefore, it is intended that all such changes and modifications within the scope of the invention be covered in the appended claims.

Claims

1. A treatment composition comprising at least one fragrance raw material and an esteramine of formula (I) or a salt thereof, 【Chemistry 1】 In the formula, independently of each other: t is an integer between 1 and 100; A １ For each repeating unit t, independently selected from the list consisting of ethyleneoxy group, 1,2-propyleneoxy group, 1,2-butyleneoxy group, 2,3-butyleneoxy group, i-butyleneoxy group, pentyleneoxy group, hexyleneoxy group, styryloxy group, decenyloxy group, dodecenyloxy group, tetradecenyloxy group, and hexadecanyloxy group, if t is equal to 1, A １ The oxygen atom of the group is bonded to the B group, and the next A １ The group always has an oxygen atom, and the previous A １ Base link; B １ is, independently of each other, a linking, linear C １ -C １２ alkanediyl group, and a branched C １ -C １２ alkanediyl group selected from the group consisting of; R ４ , R ８ , and R １２ is selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; However, Z １ These include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and compounds according to formula (II): 【Chemistry 2】 [In the formula, they are independent of each other, w is an integer between 0 and 12; R １３ and R １４ Each repeating unit w is independently selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl; R １５ , R １６ , R １７ , and R １８ [Selected from the group consisting of H, linear alkyl, branched alkyl, and cycloalkyl] A compound according to formula (II) is selected from the group consisting of the above, ＊ The compound according to formula (I) is connected via a bond labeled with R, where R ４ , R ８ , and / or R １２ A treatment composition wherein at least one of the elements contains at least seven or more carbon atoms.

2. The treatment composition according to claim 1, comprising a salt of the esteramine, wherein the salt is formed by at least partial protonation of an amine group with an acid that is a protic organic acid or an inorganic acid.

3. The treatment composition according to claim 1 or 2, wherein the salt is formed by at least partial protonation of an amine group with an acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, and lactic acid.

4. A １ The treatment composition according to any one of claims 1 to 3, wherein each repeating unit t is independently selected from a list consisting of an ethyleneoxy group, a 1,2-propyleneoxy group, and a 1,2-butyleneoxy group.

5. Z １ w is selected from the group consisting of alanine, glycine, lysine, and compounds according to formula (II), w is an integer in the range of 1 to 4, and the compounds according to formula (II) are ＊ The bond labeled with connects to the compound according to formula (I), wherein at least one group R ４ , R ８ , and / or R １２ The treatment composition according to any one of claims 1 to 4, wherein the composition contains at least seven carbon atoms.

6. A processed composition comprising at least one fragrance raw material and an esteramine or a salt thereof, wherein the esteramine or salt thereof is obtained by a method using a catalytic amount of at least one orthoester, the method being: a) i) α-, β-, γ-, δ-, ε-amino acids such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamate, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, and serine; α-amino acids having secondary or tertiary amino groups such as sarcosine and N,N-dimethylglycine; 6-aminohexanoic acid, 4-aminobutanoic acid, 3-aminopropanoic acid, 12-aminododecanoic acid, and 11-aminoundecanoic acid. At least one amino acid selected from other amino acids such as hydroxy acids; amino acids formally derived from hydrolysis of α-lactams (3 ring atoms), β-lactams (4 ring atoms), γ-lactams (5 ring atoms), etc., wherein such lactams are preferably β-propiolactam, γ-butyrolactam, δ-valerolactam, γ-valerolactam, e-caprolactam, d-decalactam, γ-decalactam, e-decalactam; preferably at least one amino acid is alanine, valine, β-alanine, 6-aminohexanoic acid. ii) At least one alcohol (A) having at least one hydroxyl group, selected from mono-, di-, and polyols, all of which may optionally be alkoxylated, wherein the alkoxylation of at least one hydroxyl group is carried out in a step prior to step a), and the alcohol is alkoxylated with at least one alkylene oxide per hydroxyl group, preferably at least 1 and up to 200, preferably 1 to 100, more preferably up to 50 moles of alkylene oxide, iii) At least one acid (C) selected from inorganic and organic acids, wherein the organic or inorganic acid preferably has a pKa value in the range of -3 to +5, more preferably -2.5 to 1.5, and preferably at least one organic acid such as a sulfonic acid, more preferably an alkyl sulfonic acid and / or an aryl sulfonic acid. In the presence of; iv) A step of obtaining an esteramine salt by a reaction in the presence of at least one orthoester such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, etc., wherein the orthoester is used in less than a stoichiometric amount, preferably a catalytic amount (relative to the amino acid), On the other hand, the alcohol used in esterification is different from the alcohol residue in the orthoester, and the process is different. b) A step of optionally neutralizing the obtained esteramine salt with at least one base to obtain a free esteramine, Includes, The processed composition contains less than 0.5% by weight of alcohol (A) of the total composition as a residue of the reaction process used to obtain the esteramine or a salt thereof. Processing composition.

7. The aforementioned alcohol (A) is: a. Non-alkoxylated linear C2-C36 alcohols such as monoalcohols including C1-C36 alkanols, preferably C6-C22 fatty alcohols, more preferably C8-C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, and most preferably a mixture of alcohols selected from C16 and C18 fatty alcohols; non-alkoxylated branched C3-C36 alcohols such as 2-ethylhexanol, 2-propylheptanol, isotridecanol, isononanol, and C9-C17 oxoalcohols; Alkoxylated linear C2-C36 alcohols such as alkoxylated mixtures of C6-C22 fatty alcohols, preferably alkoxylated mixtures of C8-C22 fatty alcohols, more preferably alkoxylated mixtures of C12-C14 fatty alcohols, and most preferably alkoxylated mixtures of C16-C18 fatty alcohols; Monoalcohols selected from the group consisting of alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, and alkoxylated branched C3-C36 alcohols such as alkoxylated C9-C17 oxoalcohols; b. Dialcohols such as alkanediols and polyalkoxylated C2-C6 alkanediols having at least two hydroxyl groups; c. Oligo-alcohols such as polyalkoxylated C3-C6 alkanetriols having at least three hydroxyl groups; d. Polyols such as sugar alcohols, polyalkoxylated C5-C6 alkane polyols, diglycerols, triglycerol polyglycerols, dipentaerythritol, tripentaerythritol, and other glycerols; and / or e. Phenoxyalkanols such as phenoxyethanol; Selected from, Alcohols selected from the group consisting of monoalcohols, alkoxylated di- and oligo-alcohols, and alkoxylated polyols are preferred. Alcohols selected from the group of monoalcohols and alkoxylated dialcohols are more preferably, The treatment composition according to claim 6.

8. The alcohol (A) used is an alkoxylated alcohol obtained by alkoxyling at least one hydroxyl group of the alcohol described in claim 2 with one or more alkylene oxides to produce an alkylene oxy chain containing one or more portions derived from alkylene oxides selected from C2 to C22 alkylene oxides, preferably C2 to C4 alkylene oxides. The alkylene oxide-derived portions may be arranged randomly, in blocks, or in multi-blocks, or in combination thereof, preferably as blocks, more preferably containing only one block made of ethylene oxide, or consisting of two blocks, where a first block (preferably an "inner block" directly bonded to the hydroxyl group of an alcohol) is made of ethylene oxide and a second block (preferably an "outer block" bonded to the ethylene oxide block) is made of propylene oxide, and such a diblock more preferably consists of 3 to 10 EO-derived portions, and the PO block consists of 1 to 10 PO-derived portions. The treatment composition according to claim 6 or 7.

9. The acid (C) is as follows: i) Alkyl sulfonic acids such as methanesulfonic acid, ethylsulfonic acid, propylsulfonic acid, and camphorsulfonic acid; toluenesulfonic acid (including mixtures thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (mixtures thereof), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid, and naphthalenesulfonic acid; specifically, alkylbenzenesulfonic acid, preferably p-toluenesulfonic acid and methanesulfonic acid, more preferably methanesulfonic acid; ii) Inorganic acids such as hydrochloric acid, hydrobromic acid, and phosphoric acid; A treatment composition according to any one of claims 6 to 8, selected from, preferably from group i).

10. The treatment composition according to any one of claims 6 to 9, wherein the acid (C) is selected so that the esteramine is obtained as a salt in cationic form, preferably the selected acid is methanesulfonic acid, and the obtained esteramine is a salt in cationic form.

11. The treated composition according to any one of claims 6 to 10, wherein the molar ratio of amino acids to hydroxyl groups of (optionally alkoxylated) alcohols is (0.8 × n):1 to (1 × n):1.5, and the number of hydroxyl groups of (optionally alkoxylated) alcohols is n.

12. The treatment composition according to any one of claims 6 to 11, wherein the method is carried out in a molar ratio of the acid (C) to the amino acid in the range of 0.8:1 to 1:1.

2.

13. In the above method, the reaction occurs under the following conditions: a. At temperatures between 50 and 200°C, preferably 70 and 180°C, more preferably 80 and 160°C, and most preferably between 120°C and 150°C, such as 60, 65, 75, 85, 90, 95, 100, 110, 115, 120, 125, 130, 135, 140, 145, 155, 165, 170, and 190°C; b. Over a period of time such as 1 to 30 hours, preferably from 2 hours, more preferably from 3 hours, even more preferably at least 5 hours, preferably up to 48 hours, more preferably up to 20 hours, even more preferably up to 15 hours, preferably 3 to 24 hours, more preferably 5 to 24 hours, most preferably 10 to 24 hours; c. At a pressure of 0.001 to 10 bar, more preferably 1 to 5 bar, more preferably 1 to 4 bar, etc., from 0.001 bar, more preferably 0.005 bar, even more preferably 0.1 bar, preferably up to 8 bar, more preferably up to 5 bar, even more preferably up to 4 bar, etc., or at a pressure of 0.001 to 10 bar, such as 1 to 1000 mbar, more preferably 100 to 500 mbar, etc. A treatment composition according to any one of claims 6 to 12, which is implemented.

14. The treatment composition according to any one of claims 6 to 13, wherein the solvent for the reaction is selected from water, toluene, xylene, heptanol, cyclohexene, and the like, and preferably is water alone.

15. The treated composition according to any one of claims 6 to 14, wherein during or after the reaction, preferably at least during the reaction, water and / or excess alcohol are removed, preferably by applying a gas stream using an inert gas such as nitrogen or argon, preferably a gas such as vapor made from nitrogen or water, preferably by applying a gas stream using an inert gas, more preferably nitrogen, and / or by distillation, preferably distillation, more preferably by distillation under reduced pressure and / or at high temperature, preferably both, a more preferred method being the use of an apparatus such as a Dean-Stark trap, most preferably using a Dean-Stark trap, and such removal is carried out using a high temperature and more preferably by applying a vacuum in the range of 0.1 mbar to 800 mbar, preferably 1 mbar to 500 mbar, more preferably 10 mbar to 100 mbar.

Images